<!DOCTYPE html>
<html lang="en" class="no-js">
    <head>
        <title>Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C &gt; T have a prognostic value in acute myeloid leukemia | Biomarker Research | Full Text</title>

        
    
        
    


        
        
    
    <meta name="journal_id" content='40364'/>
    
    <meta name="dc.title" content='Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C&#8201;&gt;&#8201;T have a prognostic value in acute myeloid leukemia'/>
    
    <meta name="dc.description" content='The isocitrate dehydrogenase (IDH1/IDH2) genes are metabolic enzymes, which are frequently mutated in acute myeloid leukemia (AML). The enzymes acquire neomorphic enzymatic activity when they mutated. We have investigated the frequency and outcome of the acquired IDH1/IDH2 mutations and the IDH1 SNP 105C&#8201;&gt;&#8201;T (rs11554137) in 189 unselected de novo AML patients by polymerase chain reaction amplification followed by direct sequencing. The survival are presented in Kaplan Meier curves with log rank test. Multivariable survival analysis was conducted using Cox regression method, taking age, risk group, treatment, IDH1/2 mutations and IDH1 SNP105 genotype into account. Overall, IDH1/2 mutations were found in 41/187 (21.7%) of the AML patients. IDH1 codon 132 mutations were present in 7.9%, whereas IDH2 mutations were more frequent and mutations were identified in codon 140 and 172 in a frequency of 11.1% and 2.6%, respectively. The SNP 105C&#8201;&gt;&#8201;T was present in 10.5% of the patients, similar to the normal population. A significantly reduced overall survival (OS) for patients carrying IDH2 codon 140 mutation compared with patients carrying wild-type IDH2 gene (p&#8201;&lt;&#8201;0.001) was observed in the intermediate risk patient group. Neither in the entire patient group nor subdivided in different risk groups, IDH1 mutations had any significance on OS compared to the wild-type IDH1 patients. A significant difference in OS between the heterozygous SNP variant and the homozygous wild-type was observed in the intermediate risk FLT3 negative AML patients (p&#8201;=&#8201;0.004). Our results indicate that AML-patients with IDH2 mutations or the IDH1 SNP 105C&#8201;&gt;&#8201;T variant can represent a new subgroup for risk stratification and may indicate new treatment options.'/>
    
    <meta name="dc.source" content='Biomarker Research 2014 2:1'/>
    
    <meta name="dc.format" content='text/html'/>
    
    <meta name="dc.publisher" content='BioMed Central'/>
    
    <meta name="dc.date" content='2014-10-08'/>
    
    <meta name="dc.type" content='OriginalPaper'/>
    
    <meta name="dc.language" content='En'/>
    
    <meta name="dc.copyright" content='2014 Willander et al.; licensee BioMed Central Ltd.'/>
    
    <meta name="dc.rights" content='http://creativecommons.org/licenses/by/4.0'/>
    
    <meta name="dc.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.issn" content='2050-7771'/>
    
    <meta name="prism.publicationName" content='Biomarker Research'/>
    
    <meta name="prism.publicationDate" content='2014-10-08'/>
    
    <meta name="prism.volume" content='2'/>
    
    <meta name="prism.number" content='1'/>
    
    <meta name="prism.section" content='OriginalPaper'/>
    
    <meta name="prism.startingPage" content='18'/>
    
    <meta name="prism.copyright" content='2014 Willander et al.; licensee BioMed Central Ltd.'/>
    
    <meta name="prism.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.url" content='https://biomarkerres.biomedcentral.com/articles/10.1186/2050-7771-2-18'/>
    
    <meta name="citation_pdf_url" content='https://biomarkerres.biomedcentral.com/track/pdf/10.1186/2050-7771-2-18?site=biomarkerres.biomedcentral.com'/>
    
    <meta name="citation_abstract_html_url" content='https://biomarkerres.biomedcentral.com/articles/10.1186/2050-7771-2-18'/>
    
    <meta name="citation_fulltext_html_url" content='https://biomarkerres.biomedcentral.com/articles/10.1186/2050-7771-2-18'/>
    
    <meta name="citation_journal_title" content='Biomarker Research'/>
    
    <meta name="citation_publisher" content='BioMed Central'/>
    
    <meta name="citation_issn" content='2050-7771'/>
    
    <meta name="citation_title" content='Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C&#8201;&gt;&#8201;T have a prognostic value in acute myeloid leukemia'/>
    
    <meta name="citation_volume" content='2'/>
    
    <meta name="citation_issue" content='1'/>
    
    <meta name="citation_date" content='2014/10/08'/>
    
    <meta name="citation_publication_date" content='2014/10/08'/>
    
    <meta name="citation_firstpage" content='18'/>
    
    <meta name="citation_article_type" content='Research'/>
    
    <meta name="citation_fulltext_world_readable" content=''/>
    
    <meta name="dc.creator" content='Kerstin Willander'/>
    
    <meta name="dc.creator" content='Ingrid Jakobsen Falk'/>
    
    <meta name="dc.creator" content='Roza Chaireti'/>
    
    <meta name="dc.creator" content='Esbj&#246;rn Paul'/>
    
    <meta name="dc.creator" content='Monica Hermansson'/>
    
    <meta name="dc.creator" content='Henrik Gr&#233;en'/>
    
    <meta name="dc.creator" content='Kourosh Lotfi'/>
    
    <meta name="dc.creator" content='Peter S&#246;derkvist'/>
    
    <meta name="dc.subject" content='Biomedicine general'/>
    
    <meta name="dc.subject" content='Cancer Research'/>
    
    <meta name="dc.subject" content='Neurosciences'/>
    
    <meta name="citation_author" content='Kerstin Willander'/>
    
    <meta name="citation_author_institution" content='Department of Clinical and Experimental Medicine, Link&#246;ping University, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author_institution" content='Department of Hematology, County Council of &#214;sterg&#246;tland, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author" content='Ingrid Jakobsen Falk'/>
    
    <meta name="citation_author_institution" content='Department of Medical and Health Sciences, Link&#246;ping University, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author" content='Roza Chaireti'/>
    
    <meta name="citation_author_institution" content='Department of Hematology, County Council of &#214;sterg&#246;tland, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author" content='Esbj&#246;rn Paul'/>
    
    <meta name="citation_author_institution" content='Division of Hematology, Department of Medicine, Karolinska Institutet, Huddinge, Sweden'/>
    
    <meta name="citation_author" content='Monica Hermansson'/>
    
    <meta name="citation_author_institution" content='Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden'/>
    
    <meta name="citation_author" content='Henrik Gr&#233;en'/>
    
    <meta name="citation_author_institution" content='Department of Medical and Health Sciences, Link&#246;ping University, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author_institution" content='Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author" content='Kourosh Lotfi'/>
    
    <meta name="citation_author_institution" content='Department of Medical and Health Sciences, Link&#246;ping University, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author_institution" content='Department of Hematology, County Council of &#214;sterg&#246;tland, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author" content='Peter S&#246;derkvist'/>
    
    <meta name="citation_author_institution" content='Department of Clinical and Experimental Medicine, Link&#246;ping University, Link&#246;ping, Sweden'/>
    
    <meta name="citation_author_institution" content='Department of Clinical Genetics, County Council of &#214;sterg&#246;tland, Link&#246;ping, Sweden'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children&#8217;s Leukaemia Working Parties; citation_author=D Grimwade; citation_author=H Walker; citation_author=F Oliver; citation_author=K Wheatley; citation_author=C Harrison; citation_author=G Harrison; citation_author=J Rees; citation_author=I Hann; citation_author=R Stevens; citation_author=A Burnett; citation_author=A Goldstone; citation_volume=92; citation_publication_date=1998; citation_pages=2322-2333; citation_id=CR1;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial; citation_author=D Grimwade; citation_author=H Walker; citation_author=G Harrison; citation_author=F Oliver; citation_author=S Chatters; citation_author=CJ Harrison; citation_author=K Wheatley; citation_author=AK Burnett; citation_author=AH Goldstone; citation_volume=98; citation_publication_date=2001; citation_pages=1312-1320; citation_doi=10.1182/blood.V98.5.1312; citation_id=CR2;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Implications of NRAS mutations in AML: a study of 2502 patients; citation_author=U Bacher; citation_author=T Haferlach; citation_author=C Schoch; citation_author=W Kern; citation_author=S Schnittger; citation_volume=107; citation_publication_date=2006; citation_pages=3847-3853; citation_doi=10.1182/blood-2005-08-3522; citation_id=CR3;'/>
    
    <meta name="citation_reference" content='citation_journal_title=CA Cancer J Clin; citation_title=The difficult problem of acute myeloid leukemia in the older adult; citation_author=RM Stone; citation_volume=52; citation_publication_date=2002; citation_pages=363-371; citation_doi=10.3322/canjclin.52.6.363; citation_id=CR4;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype; citation_author=B Falini; citation_author=C Mecucci; citation_author=E Tiacci; citation_author=M Alcalay; citation_author=R Rosati; citation_author=L Pasqualucci; citation_author=R La Starza; citation_author=D Diverio; citation_author=E Colombo; citation_author=A Santucci; citation_author=B Bigerna; citation_author=R Pacini; citation_author=A Pucciarini; citation_author=A Liso; citation_author=M Vignetti; citation_author=P Fazi; citation_author=N Meani; citation_author=V Pettirossi; citation_author=G Saglio; citation_author=F Mandelli; citation_author=F Lo-Coco; citation_author=PG Pelicci; citation_author=MF Martelli; citation_volume=352; citation_publication_date=2005; citation_pages=254-266; citation_doi=10.1056/NEJMoa041974; citation_id=CR5;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Clin Cancer Res; citation_title=Risk assessment in patients with acute myeloid leukemia and a normal karyotype; citation_author=M Bienz; citation_author=M Ludwig; citation_author=EO Leibundgut; citation_author=BU Mueller; citation_author=D Ratschiller; citation_author=M Solenthaler; citation_author=MF Fey; citation_author=T Pabst; citation_volume=11; citation_publication_date=2005; citation_pages=1416-1424; citation_doi=10.1158/1078-0432.CCR-04-1552; citation_id=CR6;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Internal tandem duplication of the flt3 gene found in acute myeloid leukemia; citation_author=M Nakao; citation_author=S Yokota; citation_author=T Iwai; citation_author=H Kaneko; citation_author=S Horiike; citation_author=K Kashima; citation_author=Y Sonoda; citation_author=T Fujimoto; citation_author=S Misawa; citation_volume=10; citation_publication_date=1996; citation_pages=1911-1918; citation_id=CR7;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?; citation_author=K Mrozek; citation_author=G Marcucci; citation_author=P Paschka; citation_author=SP Whitman; citation_author=CD Bloomfield; citation_volume=109; citation_publication_date=2007; citation_pages=431-448; citation_doi=10.1182/blood-2006-06-001149; citation_id=CR8;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Recurring mutations found by sequencing an acute myeloid leukemia genome; citation_author=ER Mardis; citation_author=L Ding; citation_author=DJ Dooling; citation_author=DE Larson; citation_author=MD McLellan; citation_author=K Chen; citation_author=DC Koboldt; citation_author=RS Fulton; citation_author=KD Delehaunty; citation_author=SD McGrath; citation_author=LA Fulton; citation_author=DP Locke; citation_author=VJ Magrini; citation_author=RM Abbott; citation_author=TL Vickery; citation_author=JS Reed; citation_author=JS Robinson; citation_author=T Wylie; citation_author=SM Smith; citation_author=L Carmichael; citation_author=JM Eldred; citation_author=CC Harris; citation_author=J Walker; citation_author=JB Peck; citation_author=F Du; citation_author=AF Dukes; citation_author=GE Sanderson; citation_author=AM Brummett; citation_author=E Clark; citation_author=JF McMichael; citation_volume=361; citation_publication_date=2009; citation_pages=1058-1066; citation_doi=10.1056/NEJMoa0903840; citation_id=CR9;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Trends Mol Med; citation_title=IDH mutations in glioma and acute myeloid leukemia; citation_author=L Dang; citation_author=S Jin; citation_author=SM Su; citation_volume=16; citation_publication_date=2010; citation_pages=387-397; citation_doi=10.1016/j.molmed.2010.07.002; citation_id=CR10;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas; citation_author=M Sanson; citation_author=Y Marie; citation_author=S Paris; citation_author=A Idbaih; citation_author=J Laffaire; citation_author=F Ducray; citation_author=S El Hallani; citation_author=B Boisselier; citation_author=K Mokhtari; citation_author=K Hoang-Xuan; citation_author=JY Delattre; citation_volume=27; citation_publication_date=2009; citation_pages=4150-4154; citation_doi=10.1200/JCO.2009.21.9832; citation_id=CR11;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=IDH1 and IDH2 mutations in gliomas; citation_author=H Yan; citation_author=DW Parsons; citation_author=G Jin; citation_author=R McLendon; citation_author=BA Rasheed; citation_author=W Yuan; citation_author=I Kos; citation_author=I Batinic-Haberle; citation_author=S Jones; citation_author=GJ Riggins; citation_author=H Friedman; citation_author=A Friedman; citation_author=D Reardon; citation_author=J Herndon; citation_author=KW Kinzler; citation_author=VE Velculescu; citation_author=B Vogelstein; citation_author=DD Bigner; citation_volume=360; citation_publication_date=2009; citation_pages=765-773; citation_doi=10.1056/NEJMoa0808710; citation_id=CR12;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study; citation_author=G Marcucci; citation_author=K Maharry; citation_author=YZ Wu; citation_author=MD Radmacher; citation_author=K Mrozek; citation_author=D Margeson; citation_author=KB Holland; citation_author=SP Whitman; citation_author=H Becker; citation_author=S Schwind; citation_author=KH Metzeler; citation_author=BL Powell; citation_author=TH Carter; citation_author=JE Kolitz; citation_author=M Wetzler; citation_author=AJ Carroll; citation_author=MR Baer; citation_author=MA Caligiuri; citation_author=RA Larson; citation_author=CD Bloomfield; citation_volume=28; citation_publication_date=2010; citation_pages=2348-2355; citation_doi=10.1200/JCO.2009.27.3730; citation_id=CR13;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group; citation_author=N Boissel; citation_author=O Nibourel; citation_author=A Renneville; citation_author=C Gardin; citation_author=O Reman; citation_author=N Contentin; citation_author=D Bordessoule; citation_author=C Pautas; citation_author=T de Revel; citation_author=B Quesnel; citation_author=P Huchette; citation_author=N Philippe; citation_author=S Geffroy; citation_author=C Terre; citation_author=X Thomas; citation_author=S Castaigne; citation_author=H Dombret; citation_author=C Preudhomme; citation_volume=28; citation_publication_date=2010; citation_pages=3717-3723; citation_doi=10.1200/JCO.2010.28.2285; citation_id=CR14;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication; citation_author=P Paschka; citation_author=RF Schlenk; citation_author=VI Gaidzik; citation_author=M Habdank; citation_author=J Kronke; citation_author=L Bullinger; citation_author=D Spath; citation_author=S Kayser; citation_author=M Zucknick; citation_author=K Gotze; citation_author=HA Horst; citation_author=U Germing; citation_author=H D&#246;hner; citation_author=K D&#246;hner; citation_volume=28; citation_publication_date=2010; citation_pages=3636-3643; citation_doi=10.1200/JCO.2010.28.3762; citation_id=CR15;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Cancer-associated IDH1 mutations produce 2-hydroxyglutarate; citation_author=L Dang; citation_author=DW White; citation_author=S Gross; citation_author=BD Bennett; citation_author=MA Bittinger; citation_author=EM Driggers; citation_author=VR Fantin; citation_author=HG Jang; citation_author=S Jin; citation_author=MC Keenan; citation_author=KM Marks; citation_author=RM Prins; citation_author=PS Ward; citation_author=KE Yen; citation_author=LM Liau; citation_author=JD Rabinowitz; citation_author=LC Cantley; citation_author=CB Thompson; citation_author=MG Vander Heiden; citation_author=SM Su; citation_volume=462; citation_publication_date=2009; citation_pages=739-744; citation_doi=10.1038/nature08617; citation_id=CR16;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate; citation_author=PS Ward; citation_author=J Patel; citation_author=DR Wise; citation_author=O Abdel-Wahab; citation_author=BD Bennett; citation_author=HA Coller; citation_author=JR Cross; citation_author=VR Fantin; citation_author=CV Hedvat; citation_author=AE Perl; citation_author=JD Rabinowitz; citation_author=M Carroll; citation_author=SM Su; citation_author=KA Sharp; citation_author=RL Levine; citation_author=CB Thompson; citation_volume=17; citation_publication_date=2010; citation_pages=225-234; citation_doi=10.1016/j.ccr.2010.01.020; citation_id=CR17;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation; citation_author=ME Figueroa; citation_author=O Abdel-Wahab; citation_author=C Lu; citation_author=PS Ward; citation_author=J Patel; citation_author=A Shih; citation_author=Y Li; citation_author=N Bhagwat; citation_author=A Vasanthakumar; citation_author=HF Fernandez; citation_author=MS Tallman; citation_author=Z Sun; citation_author=K Wolniak; citation_author=JK Peeters; citation_author=W Liu; citation_author=SE Choe; citation_author=VR Fantin; citation_author=E Paietta; citation_author=B L&#246;wenberg; citation_author=JD Licht; citation_author=LA Godley; citation_author=R Delwel; citation_author=PJ Valk; citation_author=CB Thompson; citation_author=RL Levine; citation_author=A Melnick; citation_volume=18; citation_publication_date=2010; citation_pages=553-567; citation_doi=10.1016/j.ccr.2010.11.015; citation_id=CR18;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases; citation_author=W Xu; citation_author=H Yang; citation_author=Y Liu; citation_author=Y Yang; citation_author=P Wang; citation_author=SH Kim; citation_author=S Ito; citation_author=C Yang; citation_author=MT Xiao; citation_author=LX Liu; citation_author=WQ Jiang; citation_author=J Liu; citation_author=JY Zhang; citation_author=B Wang; citation_author=S Frye; citation_author=Y Zhang; citation_author=YH Xu; citation_author=QY Lei; citation_author=KL Guan; citation_author=SM Zhao; citation_author=Y Xiong; citation_volume=19; citation_publication_date=2011; citation_pages=17-30; citation_doi=10.1016/j.ccr.2010.12.014; citation_id=CR19;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor; citation_author=K Wagner; citation_author=F Damm; citation_author=G Gohring; citation_author=K Gorlich; citation_author=M Heuser; citation_author=I Schafer; citation_author=O Ottmann; citation_author=M Lubbert; citation_author=W Heit; citation_author=L Kanz; citation_author=G Schlimok; citation_author=AA Raghavachar; citation_author=W Fiedler; citation_author=HH Kirchner; citation_author=W Brugger; citation_author=M Zucknick; citation_author=B Schlegelberger; citation_author=G Heil; citation_author=A Ganser; citation_author=J Krauter; citation_volume=28; citation_publication_date=2010; citation_pages=2356-2364; citation_doi=10.1200/JCO.2009.27.6899; citation_id=CR20;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children&#8217;s Oncology Group and SWOG; citation_author=PA Ho; citation_author=KJ Kopecky; citation_author=TA Alonzo; citation_author=RB Gerbing; citation_author=KL Miller; citation_author=J Kuhn; citation_author=R Zeng; citation_author=RE Ries; citation_author=SC Raimondi; citation_author=BA Hirsch; citation_author=V Oehler; citation_author=CA Hurwitz; citation_author=JL Franklin; citation_author=AS Gamis; citation_author=SH Petersdorf; citation_author=JE Anderson; citation_author=JE Godwin; citation_author=GH Reaman; citation_author=CL Willman; citation_author=ID Bernstein; citation_author=JP Radich; citation_author=FR Appelbaum; citation_author=DL Stirewalt; citation_author=S Meshinchi; citation_volume=118; citation_publication_date=2011; citation_pages=4561-4566; citation_doi=10.1182/blood-2011-04-348888; citation_id=CR21;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Hum Pathol; citation_title=IDH mutations in acute myeloid leukemia; citation_author=D Rakheja; citation_author=S Konoplev; citation_author=LJ Medeiros; citation_author=W Chen; citation_volume=43; citation_publication_date=2012; citation_pages=1541-1551; citation_doi=10.1016/j.humpath.2012.05.003; citation_id=CR22;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status; citation_author=S Schnittger; citation_author=C Haferlach; citation_author=M Ulke; citation_author=T Alpermann; citation_author=W Kern; citation_author=T Haferlach; citation_volume=116; citation_publication_date=2010; citation_pages=5486-5496; citation_doi=10.1182/blood-2010-02-267955; citation_id=CR23;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia; citation_author=WC Chou; citation_author=WC Lei; citation_author=BS Ko; citation_author=HA Hou; citation_author=CY Chen; citation_author=JL Tang; citation_author=M Yao; citation_author=W Tsay; citation_author=SJ Wu; citation_author=SY Huang; citation_author=SC Hsu; citation_author=YC Chen; citation_author=YC Chang; citation_author=KT Kuo; citation_author=FY Lee; citation_author=MC Liu; citation_author=CW Liu; citation_author=MH Tseng; citation_author=CF Huang; citation_author=HF Tien; citation_volume=25; citation_publication_date=2011; citation_pages=246-253; citation_doi=10.1038/leu.2010.267; citation_id=CR24;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Am J Clin Pathol; citation_title=Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features; citation_author=KP Patel; citation_author=F Ravandi; citation_author=D Ma; citation_author=A Paladugu; citation_author=BA Barkoh; citation_author=LJ Medeiros; citation_author=R Luthra; citation_volume=135; citation_publication_date=2011; citation_pages=35-45; citation_doi=10.1309/AJCPD7NR2RMNQDVF; citation_id=CR25;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Hematol Oncol; citation_title=Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients; citation_author=S Chotirat; citation_author=W Thongnoppakhun; citation_author=O Promsuwicha; citation_author=C Boonthimat; citation_author=CU Auewarakul; citation_volume=5; citation_publication_date=2012; citation_pages=5; citation_doi=10.1186/1756-8722-5-5; citation_id=CR26;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=The prognostic significance of IDH2 mutations in AML depends on the location of the mutation; citation_author=CL Green; citation_author=CM Evans; citation_author=L Zhao; citation_author=RK Hills; citation_author=AK Burnett; citation_author=DC Linch; citation_author=RE Gale; citation_volume=118; citation_publication_date=2011; citation_pages=409-412; citation_doi=10.1182/blood-2010-12-322479; citation_id=CR27;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value; citation_author=S Abbas; citation_author=S Lugthart; citation_author=FG Kavelaars; citation_author=A Schelen; citation_author=JE Koenders; citation_author=A Zeilemaker; citation_author=WJ van Putten; citation_author=AW Rijneveld; citation_author=B Lowenberg; citation_author=PJ Valk; citation_volume=116; citation_publication_date=2010; citation_pages=2122-2126; citation_doi=10.1182/blood-2009-11-250878; citation_id=CR28;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Prognostic relevance of integrated genetic profiling in acute myeloid leukemia; citation_author=JP Patel; citation_author=M Gonen; citation_author=ME Figueroa; citation_author=H Fernandez; citation_author=Z Sun; citation_author=J Racevskis; citation_author=P Van Vlierberghe; citation_author=I Dolgalev; citation_author=S Thomas; citation_author=O Aminova; citation_author=K Huberman; citation_author=J Cheng; citation_author=A Viale; citation_author=ND Socci; citation_author=A Heguy; citation_author=A Cherry; citation_author=G Vance; citation_author=RR Higgins; citation_author=RP Ketterling; citation_author=RE Gallagher; citation_author=M Litzow; citation_author=MR van den Brink; citation_author=HM Lazarus; citation_author=JM Rowe; citation_author=S Luger; citation_author=A Ferrando; citation_author=E Paietta; citation_author=MS Tallman; citation_author=A Melnick; citation_author=O Abdel-Wahab; citation_volume=366; citation_publication_date=2012; citation_pages=1079-1089; citation_doi=10.1056/NEJMoa1112304; citation_id=CR29;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible; citation_author=JA Losman; citation_author=RE Looper; citation_author=P Koivunen; citation_author=S Lee; citation_author=RK Schneider; citation_author=C McMahon; citation_author=GS Cowley; citation_author=DE Root; citation_author=BL Ebert; citation_author=WG Kaelin; citation_volume=339; citation_publication_date=2013; citation_pages=1621-1625; citation_doi=10.1126/science.1231677; citation_id=CR30;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group; citation_author=VI Gaidzik; citation_author=P Paschka; citation_author=D Spath; citation_author=M Habdank; citation_author=CH Kohne; citation_author=U Germing; citation_author=M von Lilienfeld-Toal; citation_author=G Held; citation_author=HA Horst; citation_author=D Haase; citation_author=M Bentz; citation_author=K G&#246;tze; citation_author=H D&#246;hner; citation_author=RF Schlenk; citation_author=L Bullinger; citation_author=K D&#246;hner; citation_volume=30; citation_publication_date=2012; citation_pages=1350-1357; citation_doi=10.1200/JCO.2011.39.2886; citation_id=CR31;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=A &#8220;silent&#8221; polymorphism in the MDR1 gene changes substrate specificity; citation_author=C Kimchi-Sarfaty; citation_author=JM Oh; citation_author=IW Kim; citation_author=ZE Sauna; citation_author=AM Calcagno; citation_author=SV Ambudkar; citation_author=MM Gottesman; citation_volume=315; citation_publication_date=2007; citation_pages=525-528; citation_doi=10.1126/science.1135308; citation_id=CR32;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation; citation_author=F Wang; citation_author=J Travins; citation_author=B DeLaBarre; citation_author=V Penard-Lacronique; citation_author=S Schalm; citation_author=E Hansen; citation_author=K Straley; citation_author=A Kernytsky; citation_author=W Liu; citation_author=C Gliser; citation_author=H Yang; citation_author=S Gross; citation_author=E Artin; citation_author=V Saada; citation_author=E Mylonas; citation_author=C Quivoron; citation_author=J Popovici-Muller; citation_author=JO Saunders; citation_author=FG Salituro; citation_author=S Yan; citation_author=S Murray; citation_author=W Wei; citation_author=Y Gao; citation_author=L Dang; citation_author=M Dorsch; citation_author=S Agresta; citation_author=DP Schenkein; citation_author=SA Biller; citation_author=SM Su; citation_author=S de Botton; citation_volume=340; citation_publication_date=2013; citation_pages=622-626; citation_doi=10.1126/science.1234769; citation_id=CR33;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cell Stem Cell; citation_title=Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance; citation_author=LM Kats; citation_author=M Reschke; citation_author=R Taulli; citation_author=O Pozdnyakova; citation_author=K Burgess; citation_author=P Bhargava; citation_author=K Straley; citation_author=R Karnik; citation_author=A Meissner; citation_author=D Small; citation_author=SM Su; citation_author=K Yen; citation_author=J Zhang; citation_author=PP Pandolfi; citation_volume=14; citation_publication_date=2014; citation_pages=329-341; citation_doi=10.1016/j.stem.2013.12.016; citation_id=CR34;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet; citation_author=H Dohner; citation_author=EH Estey; citation_author=S Amadori; citation_author=FR Appelbaum; citation_author=T Buchner; citation_author=AK Burnett; citation_author=H Dombret; citation_author=P Fenaux; citation_author=D Grimwade; citation_author=RA Larson; citation_author=F Lo-Coco; citation_author=T Naoe; citation_author=D Niederwieser; citation_author=GJ Ossenkoppele; citation_author=MA Sanz; citation_author=J Sierra; citation_author=MS Tallman; citation_author=B L&#246;wenberg; citation_author=CD Bloomfield; citation_volume=115; citation_publication_date=2010; citation_pages=453-474; citation_doi=10.1182/blood-2009-07-235358; citation_id=CR35;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia; citation_author=BD Cheson; citation_author=JM Bennett; citation_author=KJ Kopecky; citation_author=T Buchner; citation_author=CL Willman; citation_author=EH Estey; citation_author=CA Schiffer; citation_author=H Doehner; citation_author=MS Tallman; citation_author=TA Lister; citation_author=F Lo-Coco; citation_author=R Willemze; citation_author=A Biondi; citation_author=W Hiddemann; citation_author=RA Larson; citation_author=B L&#246;wenberg; citation_author=MA Sanz; citation_author=DR Head; citation_author=R Ohno; citation_author=CD Bloomfield; citation_volume=21; citation_publication_date=2003; citation_pages=4642-4649; citation_doi=10.1200/JCO.2003.04.036; citation_id=CR36;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Eur J Haematol; citation_title=Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study; citation_author=A Wahlin; citation_author=R Billstrom; citation_author=O Bjor; citation_author=T Ahlgren; citation_author=M Hedenus; citation_author=M Hoglund; citation_author=A Lindmark; citation_author=B Markevarn; citation_author=B Nilsson; citation_author=B Sallerfors; citation_author=M Brune; citation_volume=83; citation_publication_date=2009; citation_pages=99-107; citation_doi=10.1111/j.1600-0609.2009.01256.x; citation_id=CR37;'/>
    
    <meta name="prism.doi" content='10.1186/2050-7771-2-18'/>
    
    <meta name="dc.identifier" content='10.1186/2050-7771-2-18'/>
    
    <meta name="citation_doi" content='10.1186/2050-7771-2-18'/>
    
    <meta name="citation_abstract" content='&lt;h2&gt;Abstract&lt;/h2&gt; &lt;h3&gt;Background&lt;/h3&gt; The isocitrate dehydrogenase (&lt;i&gt;IDH1/IDH2&lt;/i&gt;) genes are metabolic enzymes, which are frequently mutated in acute myeloid leukemia (AML). The enzymes acquire neomorphic enzymatic activity when they mutated.  &lt;h3&gt;Methods&lt;/h3&gt; We have investigated the frequency and outcome of the acquired &lt;i&gt;IDH1/IDH2&lt;/i&gt; mutations and the &lt;i&gt;IDH1&lt;/i&gt; SNP 105C&#8201;&amp;gt;&#8201;T (&lt;i&gt;rs11554137&lt;/i&gt;) in 189 unselected &lt;i&gt;de novo&lt;/i&gt; AML patients by polymerase chain reaction amplification followed by direct sequencing. The survival are presented in Kaplan Meier curves with log rank test. Multivariable survival analysis was conducted using Cox regression method, taking age, risk group, treatment, &lt;i&gt;IDH1/2&lt;/i&gt; mutations and &lt;i&gt;IDH1&lt;/i&gt; SNP105 genotype into account.  &lt;h3&gt;Results&lt;/h3&gt; Overall, &lt;i&gt;IDH1/2&lt;/i&gt; mutations were found in 41/187 (21.7%) of the AML patients. &lt;i&gt;IDH1&lt;/i&gt; codon 132 mutations were present in 7.9%, whereas &lt;i&gt;IDH2&lt;/i&gt; mutations were more frequent and mutations were identified in codon 140 and 172 in a frequency of 11.1% and 2.6%, respectively. The SNP 105C&#8201;&amp;gt;&#8201;T was present in 10.5% of the patients, similar to the normal population. A significantly reduced overall survival (OS) for patients carrying &lt;i&gt;IDH2&lt;/i&gt; codon 140 mutation compared with patients carrying wild-type &lt;i&gt;IDH2&lt;/i&gt; gene (p&#8201;&amp;lt;&#8201;0.001) was observed in the intermediate risk patient group. Neither in the entire patient group nor subdivided in different risk groups, &lt;i&gt;IDH1&lt;/i&gt; mutations had any significance on OS compared to the wild-type &lt;i&gt;IDH1&lt;/i&gt; patients. A significant difference in OS between the heterozygous SNP variant and the homozygous wild-type was observed in the intermediate risk &lt;i&gt;FLT3&lt;/i&gt; negative AML patients (p&#8201;=&#8201;0.004).  &lt;h3&gt;Conclusions&lt;/h3&gt; Our results indicate that AML-patients with &lt;i&gt;IDH2&lt;/i&gt; mutations or the &lt;i&gt;IDH1&lt;/i&gt; SNP 105C&#8201;&amp;gt;&#8201;T variant can represent a new subgroup for risk stratification and may indicate new treatment options.'/>
    
    <meta name="DOI" content='10.1186/2050-7771-2-18'/>
    

        
    <script type="text/javascript">
        dataLayer = [{"content":{"article":{"doi":"10.1186/2050-7771-2-18","articleType":"Research","peerReviewType":"Closed"},"contentInfo":{"imprint":"BioMed Central","title":"Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia","publishedAt":1412726400000,"publishedAtDate":"2014-10-08","authors":["Kerstin Willander","Ingrid Jakobsen Falk","Roza Chaireti","Esbjörn Paul","Monica Hermansson","Henrik Gréen","Kourosh Lotfi","Peter Söderkvist"],"collections":[]},"attributes":{"deliveryPlatform":"oscar","template":null,"cms":null,"copyright":{"creativeCommonsType":null}},"journal":{"volume":"2","issue":"1","title":"Biomarker Research","category":"AJ","id":40364},"category":{"pmc":{"primarySubject":"Biomedicine"}}}}]

    </script>

        

        <meta charset="UTF-8"/>
        <meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <meta name="viewport" content="width=device-width, initial-scale=1"/>
        <!-- For IE 9 and below -->
<!--[if IE]><link rel="shortcut icon" href=/static/images/favicons/biomedcentral/favicon-dc10a51d5f.ico><![endif]-->
<!-- Touch Icons - iOS and Android 2.1+ -->
<link rel="apple-touch-icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
<!-- Firefox, Chrome, Safari, IE 11+ and Opera -->
<link rel="icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
        <script>(function(H){H.className=H.className.replace(/\bno-js\b/,'js')})(document.documentElement)</script>
        <script>(function(d) {if (sessionStorage.getItem('webfonts') == 'true'){d.className += ' webfonts-loaded';}})(document.documentElement);</script>
        <link rel="stylesheet" media="screen" href=/static/styles/basic/basic-8a9ed7dce9.css>
<link rel="stylesheet" media="print" href=/static/styles/biomedcentral/biomedcentral-print-9d9c0bc8d5.css>

<link rel="stylesheet" class="js-ctm" href=/static/styles/biomedcentral/biomedcentral-1a58e9106c.css
      media="only screen and (-webkit-min-device-pixel-ratio:0) and (min-color-index:0), (-ms-high-contrast: none), only all and (min--moz-device-pixel-ratio:0) and (min-resolution: 3e1dpcm)">
        
    <script type="text/javascript">
        config = {
            env: 'live',
            site: 'biomarkerres.biomedcentral.com',
            siteWithPath: 'biomarkerres.biomedcentral.com' + window.location.pathname,
            twitterHashtag: 'biomarkerres',
            cmsPrefix: 'http://studio-cms.springer.com/studio/',
            
            doi: '10.1186/2050-7771-2-18',
            figshareScriptUrl: 'https://widgets.figshare.com/static/figshare.js',
            publisherBrand: 'BioMed Central'
        };
    </script>

        
    
    <script>
        window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;

        (function() {
            var sampleRate = 20;

            ga('create', "UA-62064032-12", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate
            });

            ga("set", "anonymizeIp", true);
            ga('send', 'pageview');

        
            ga('create', "UA-54492316-9", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate,
                name: 'global'
            });
            ga("global.set", "anonymizeIp", true);
            ga('global.send', 'pageview');
            ga('set', 'transport', 'beacon');
        
        }())
    </script>
    <script async src='https://www.google-analytics.com/analytics.js'></script>
    

        
    
    <link rel="canonical" href="//biomarkerres.biomedcentral.com/articles/10.1186/2050-7771-2-18"/>
    


        

        
        
    <meta property="og:url" content="https://biomarkerres.biomedcentral.com/articles/10.1186/2050-7771-2-18"/>
    <meta property="og:type" content="article"/>
    <meta property="og:site_name" content="Biomarker Research"/>
    <meta property="og:title" content="Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C &gt; T have a prognostic value in acute myeloid leukemia"/>
    <meta property="og:description" content="The isocitrate dehydrogenase (IDH1/IDH2) genes are metabolic enzymes, which are frequently mutated in acute myeloid leukemia (AML). The enzymes acquire neomorphic enzymatic activity when they mutated. We have investigated the frequency and outcome of the acquired IDH1/IDH2 mutations and the IDH1 SNP 105C &gt; T (rs11554137) in 189 unselected de novo AML patients by polymerase chain reaction amplification followed by direct sequencing. The survival are presented in Kaplan Meier curves with log rank test. Multivariable survival analysis was conducted using Cox regression method, taking age, risk group, treatment, IDH1/2 mutations and IDH1 SNP105 genotype into account. Overall, IDH1/2 mutations were found in 41/187 (21.7%) of the AML patients. IDH1 codon 132 mutations were present in 7.9%, whereas IDH2 mutations were more frequent and mutations were identified in codon 140 and 172 in a frequency of 11.1% and 2.6%, respectively. The SNP 105C &gt; T was present in 10.5% of the patients, similar to the normal population. A significantly reduced overall survival (OS) for patients carrying IDH2 codon 140 mutation compared with patients carrying wild-type IDH2 gene (p &lt; 0.001) was observed in the intermediate risk patient group. Neither in the entire patient group nor subdivided in different risk groups, IDH1 mutations had any significance on OS compared to the wild-type IDH1 patients. A significant difference in OS between the heterozygous SNP variant and the homozygous wild-type was observed in the intermediate risk FLT3 negative AML patients (p &#x3D; 0.004). Our results indicate that AML-patients with IDH2 mutations or the IDH1 SNP 105C &gt; T variant can represent a new subgroup for risk stratification and may indicate new treatment options."/>
    <meta property="og:image" content="https://images.springer.com/sgw/journals/medium/40364.jpg"/>

        
    </head>

    <body class="fulltext" >
    
    
        
    

    
    <div class="container" style="height: 0"><div id="wt_refpoint"></div></div>
    <p class="skip-to-main">
    <a class="skip-to-main__link" href="#main">Skip to main content</a>
</p>

    <div id="top">
        
<div id="RealMediaLeaderboard" class="adsbox RealMediaAd Ad Ad--leaderboard" data-position="Top">
    <div class="Ad_content">
        <p class="Ad_label">Advertisement</p>
        
    </div>
</div>


        



         
    <div id="membership-message-loader-desktop" class="placeholder" data-placeholder="/placeholder/v1/membership/message"></div>
    <header class="header" role="banner">
        <div class="header__inner">
            <a id="header-logo" href="//www.biomedcentral.com/" class="logo header__logo" title="BioMed Central">
                <img srcset="/static/images/biomed-central-logo-976eb64772.svg" src="/static/images/biomed-central-logo-5300b47908.png" class="logo__img" alt="Biomed Central" />
            </a>
            <div class="header__right">
                <div class="toggles js-fade-toggle">
                    <p id="loginLink" class="sign-in toggles__item" data-replace="true" data-placeholder="/placeholder/v1/username">
    <a class="sign-in__link" href="//www.biomedcentral.com/login" data-track-event="click" data-event-category="Account" data-event-action="Click Login Link">
        <span class="sign-in__no-js-account-hide">Login
            <span class="sign-in__js-account-hide"> to </span>
        </span>
        <span class="sign-in__js-account-hide sign-in__no-js-capitalise">your account</span>
    </a>
</p>
                    
                    <a href="#globalSearch" class="toggles__item toggles__item--search" data-toggle="search"><span class="sr-only">Search</span></a>
                </div>
                <form role="search" id="globalSearch" class="search search--expandable header__search" method="GET" action="//www.biomedcentral.com/search" data-track-event="submit"
      data-event-category="Search and Results" data-event-action="Submit search" data-event-label="">
    <div class="search__content">
        <label for="publisherSearch" class="sr-only">Search BioMed Central articles</label>
        <input id="publisherSearch" class="search__input" autocomplete="off" role="textbox" name="query" type="text" value="" title="Search BioMed Central" placeholder="Search BioMed Central articles"/>
        <button id="search" class="search__button" type="submit">
            <span class="sr-only">Search</span>
        </button>
        <input type="hidden" name="searchType" value="publisherSearch"/>
    </div>
</form>

            </div>
            
        </div>
    </header>

        <main role="main">
            
            <header class="journal-header" role="banner">
                <div class="journal-header__inner">
                    <h2 class="journal-header__title journal-header__title--medium" id="journalTitle">
                        
                        <a class="journal-header__title-text" href="/">
                            Biomarker Research
                        </a>
                    </h2>
                    
                </div>
                <div class="navbar">
                    <div class="navbar__inner">
                        

                        
                        <nav class="navbar__nav">
                            <h3 class="navbar__menu-toggle" data-toggle="collapse" data-target="journal-menu">
                                <span class="sr-only">Main </span>menu
                            </h3>
                            <ul id="journal-menu" class="navbar__menu" id="siteNavigation" role="menu">
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/'>Home</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/about'>About</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link is-active" href='/articles'>Articles</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/submission-guidelines'>Submission Guidelines</a>
                                    </li>
                                
                            </ul>
                        </nav>
                        
                    </div>
                </div>
                <div class="journal-identity journal-identity--globules-green">
                    
                </div>
            </header>
            
        
            <div class="container">
                
                <div id="main" class="layout">
                
                    <div class="layout__main--wide" id="main-content">
                        <div class="block" id="Test-ImgSrc">
                            
                            
    <div class="FulltextWrapper">
        <div class="Categories">
            <div class="ArticleCategory">Research</div>
            <div class="OpenAccessLabel">Open Access</div>
            
        </div>
        
    </div>

                            <div class="FulltextWrapper"><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="MainTitleSection"><h1 xmlns="http://www.w3.org/1999/xhtml" class="ArticleTitle" lang="en">Mutations in the isocitrate dehydrogenase 2 gene and <em xmlns="" class="EmphasisTypeItalic">IDH1</em> SNP 105C &gt; T have a prognostic value in acute myeloid leukemia</h1></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="AuthorNames" data-author-affiliations="true"><ul class="u-listReset"><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Kerstin&nbsp;Willander</span><sup><a href="#Aff1" class="AffiliationID">1</a>, <a href="#Aff3" class="AffiliationID">3</a></sup><a href="mailto:kerstin.willander@liu.se" class="EmailAuthor" title="Email author"><span class="ContactIcon" aria-hidden="true"></span><span class="u-srOnly">Email author</span></a>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Ingrid&nbsp;Jakobsen&nbsp;Falk</span><sup><a href="#Aff2" class="AffiliationID">2</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Roza&nbsp;Chaireti</span><sup><a href="#Aff3" class="AffiliationID">3</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Esbjörn&nbsp;Paul</span><sup><a href="#Aff4" class="AffiliationID">4</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Monica&nbsp;Hermansson</span><sup><a href="#Aff5" class="AffiliationID">5</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Henrik&nbsp;Gréen</span><sup><a href="#Aff2" class="AffiliationID">2</a>, <a href="#Aff6" class="AffiliationID">6</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Kourosh&nbsp;Lotfi</span><sup><a href="#Aff2" class="AffiliationID">2</a>, <a href="#Aff3" class="AffiliationID">3</a></sup> and </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Peter&nbsp;Söderkvist</span><sup><a href="#Aff1" class="AffiliationID">1</a>, <a href="#Aff7" class="AffiliationID">7</a></sup></li></ul></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="ArticleContextInformation"><div class="ContextInformation"><div class="ContextInformationJournalTitles"><span class="ArticleCitation"><span xmlns="http://www.w3.org/1999/xhtml" class="JournalTitle">Biomarker Research</span><span class="ArticleCitation_Year">2014</span><span class="ArticleCitation_Volume"><strong>2</strong>:18</span></span></div><p class="ArticleDOI"><a target="_blank" href="https://doi.org/10.1186/2050-7771-2-18">https://doi.org/10.1186/2050-7771-2-18</a></p><p class="Copyright">© &nbsp;Willander et al.; licensee BioMed Central Ltd.&nbsp;2014</p></div></div><div class="ArticleHistory"><p class="History HistoryReceived"><strong>Received: </strong>19&nbsp;August&nbsp;2014</p><p class="History HistoryAccepted"><strong>Accepted: </strong>2&nbsp;October&nbsp;2014</p><p class="History HistoryOnlineDate"><strong>Published: </strong>8&nbsp;October&nbsp;2014</p></div></div>
                            
                            
                            
    

                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Abstract" id="Abs1" lang="en"><h2 class="Heading js-ToggleCollapseSection">Abstract</h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec1">
                <h3 xmlns="" class="Heading">Background</h3>
                <p class="Para">The isocitrate dehydrogenase (<em xmlns="" class="EmphasisTypeItalic">IDH1/IDH2</em>) genes are metabolic enzymes, which are frequently mutated in acute myeloid leukemia (AML). The enzymes acquire neomorphic enzymatic activity when they mutated.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec2">
                <h3 xmlns="" class="Heading">Methods</h3>
                <p class="Para">We have investigated the frequency and outcome of the acquired <em xmlns="" class="EmphasisTypeItalic">IDH1/IDH2</em> mutations and the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> SNP 105C &gt; T (<em xmlns="" class="EmphasisTypeItalic">rs11554137</em>) in 189 unselected <em xmlns="" class="EmphasisTypeItalic">de novo</em> AML patients by polymerase chain reaction amplification followed by direct sequencing. The survival are presented in Kaplan Meier curves with log rank test. Multivariable survival analysis was conducted using Cox regression method, taking age, risk group, treatment, <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations and <em xmlns="" class="EmphasisTypeItalic">IDH1</em> SNP105 genotype into account.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec3">
                <h3 xmlns="" class="Heading">Results</h3>
                <p class="Para">Overall, <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations were found in 41/187 (21.7%) of the AML patients. <em xmlns="" class="EmphasisTypeItalic">IDH1</em> codon 132 mutations were present in 7.9%, whereas <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were more frequent and mutations were identified in codon 140 and 172 in a frequency of 11.1% and 2.6%, respectively. The SNP 105C &gt; T was present in 10.5% of the patients, similar to the normal population. A significantly reduced overall survival (OS) for patients carrying <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140 mutation compared with patients carrying wild-type <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene (p &lt; 0.001) was observed in the intermediate risk patient group. Neither in the entire patient group nor subdivided in different risk groups, <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations had any significance on OS compared to the wild-type <em xmlns="" class="EmphasisTypeItalic">IDH1</em> patients. A significant difference in OS between the heterozygous SNP variant and the homozygous wild-type was observed in the intermediate risk <em xmlns="" class="EmphasisTypeItalic">FLT3</em> negative AML patients (p = 0.004).</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec4">
                <h3 xmlns="" class="Heading">Conclusions</h3>
                <p class="Para">Our results indicate that AML-patients with <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations or the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> SNP 105C &gt; T variant can represent a new subgroup for risk stratification and may indicate new treatment options.</p>
              </div></div></section><div xmlns:func="http://oscar.fig.bmc.com" class="KeywordGroup" lang="en">
              <h3 xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Heading">Keywords</h3>
              <span class="Keyword">AML</span>
              <span class="Keyword">
                <em xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="EmphasisTypeItalic">IDH1</em>
              </span>
              <span class="Keyword">
                <em xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="EmphasisTypeItalic">IDH2</em>
              </span>
              <span class="Keyword">SNP</span>
              <span class="Keyword">Prognostic markers</span>
            </div>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec1" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Background</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Acute myeloid leukemia (AML) is a hematological malignancy caused by acquired genetic alterations in genes affecting the normal proliferation and terminal differentiation of myeloid progenitor cells. Based on cytogenetic abnormalities, cases of AML are usually classified into three groups, with favorable, intermediate and adverse prognosis
[<span class="CitationRef"><a href="#CR1" data-toggle="citation" data-target="CR1">1</a></span>]. The largest group is the intermediate risk group in which patients with cytogenetically normal karyotype (CN-AML) constitute about 45% of <em xmlns="" class="EmphasisTypeItalic">de novo</em> AML
[<span class="CitationRef"><a href="#CR2" data-toggle="citation" data-target="CR2">2</a></span>, <span class="CitationRef"><a href="#CR3" data-toggle="citation" data-target="CR3">3</a></span>]. These patients form a heterogeneous group where some achieve complete remission and become long term survivors, while others rapidly relapse, often with a more aggressive or resistant disease. The overall 5-year survival is 35-40%, but less than 15% in AML patients above the age of 60
[<span class="CitationRef"><a href="#CR4" data-toggle="citation" data-target="CR4">4</a></span>]. During the last decades, several new mutations with prognostic impact have been identified in AML. These include internal tandem duplications (ITDs) in the fms-like tyrosine kinase 3 (FLT3) gene, conferring an adverse prognosis, and nucleophosmine 1 (NPM1) gene mutations, which in the absence of <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD confer a favorable prognosis
[<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>–<span class="CitationRef"><a href="#CR8" data-toggle="citation" data-target="CR8">8</a></span>]. Both these genes have become clinically established prognostic markers in CN-AML. However, there is still a large group of intermediate risk patients without <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD/<em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations or other reliable prognostic markers, highlighting the need for additional markers that could explain the differential outcome in this heterogeneous patient group.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Genome-wide analysis in patients with AML have identified further genetic markers, thus extending the possibilities for more accurate prognostic distinctions between subgroups, and might aid the clinicians in treatment decisions such as choice of chemotherapy regime or early stem cell transplantation (SCT).</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The isocitrate dehydrogenase (<em xmlns="" class="EmphasisTypeItalic">IDH</em>) 1 and 2 genes were identified to be mutated in AML
[<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>]. The IDH family consists of three isoforms, IDH1, IDH2 and IDH3 where IDH1 is located in the cytosol, while IDH2 and IDH3 are located in the mitochondrion and are normally involved in citrate metabolism in the tricarboxylic acid cycle
[<span class="CitationRef"><a href="#CR10" data-toggle="citation" data-target="CR10">10</a></span>]. The IDH1 and IDH2 enzymes are encoded by the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene at chromosome 2q33 and the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene resides at chromosome 15q26. The enzymes are NADP<sup>+</sup>-dependent to catalyze isocitrate oxidation to α-ketoglutarate (α-KG) and the cofactor NADPH is generated. Mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> genes were first identified in malignant gliomas
[<span class="CitationRef"><a href="#CR11" data-toggle="citation" data-target="CR11">11</a></span>, <span class="CitationRef"><a href="#CR12" data-toggle="citation" data-target="CR12">12</a></span>] and subsequently <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations were frequently found in AML
[<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>] and later also recurrent <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were found in AML
[<span class="CitationRef"><a href="#CR13" data-toggle="citation" data-target="CR13">13</a></span>–<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>]. No mutations have been reported in the <em xmlns="" class="EmphasisTypeItalic">IDH3</em> gene. <em xmlns="" class="EmphasisTypeItalic">IDH1</em>/2 mutations are usually heterozygous with one wild-type allele and one mutant allele, affecting the arginine at codon 132 in exon 4 in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene, codon 140 and codon 172 in exon 4 in the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene. The mutants acquire neomorphic enzymatic activity by converting α-KG to 2-hydroxyglutarate (2-HG)
[<span class="CitationRef"><a href="#CR16" data-toggle="citation" data-target="CR16">16</a></span>, <span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>]. Studies have shown that <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations are associated with epigenetic alterations, by inhibiting the function of TET2, a DNA demethylase enzyme which activity is dependent on α-KG and essential for DNA demethylation. Mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> genes favour 2-HG production and decrease the amount of α-KG, resulting in a hypermethylation phenotype and impaired hematopoietic differentiation
[<span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>, <span class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>]. Further, a synonymous single nucleotide polymorphism (SNP) (<em xmlns="" class="EmphasisTypeItalic">rs11554137</em>) located in codon 105 in exon 4 in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene, was recently reported to be of prognostic value in both adult and paediatric AML patients
[<span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR21" data-toggle="citation" data-target="CR21">21</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In this study we aimed to investigate the frequency of the acquired <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations and the SNP 105C &gt; T (<em xmlns="" class="EmphasisTypeItalic">rs11554137</em>) located in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene and correlate the different genotypes to the outcome in AML patients.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec2" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Results</h2><div class="js-CollapseSection"><section id="Sec3" class="Section2 RenderAsSection2">
                <h3 class="Heading">
<em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em> mutation analysis</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">All patients were successfully genotyped for <em xmlns="" class="EmphasisTypeItalic">IDH1</em> codon 132 mutations, <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140 and codon 172 mutations, and for the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> codon 105 SNP (<em xmlns="" class="EmphasisTypeItalic">rs11554137</em>) (Table&nbsp;
<span class="InternalRef"><a href="#Tab1">1</a></span>). Mutational data distributions in the entire cohort and in patient subgroups are presented in Table&nbsp;
<span class="InternalRef"><a href="#Tab2">2</a></span>. In total, <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations were found in 41/189 (21.7%) of the AML patients. Fifteen patients (7.9%) had mutations in codon 132 in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene resulting in four different amino acid exchanges, arg &gt; his (7/15), arg &gt; cys (6/15), arg &gt; leu (1/15) and arg &gt; gly (1/15). <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were found in exon four at codon 140 in 21 (11.1%) of the patients and at codon 172 in 5 (2.6%) of the patients. For <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140 mutations, two amino acid exchanges were detected: arg &gt; gln (20/21) and arg &gt; gly (1/21). For <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 172 mutations all were arg &gt; lys exchanges (5/5). Mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene were mutually exclusive with mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene (Table&nbsp;
<span class="InternalRef"><a href="#Tab1">1</a></span>).<figure xmlns="" id="Tab1" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 1</span>
                        <p xmlns="" class="SimplePara">
<span class="EmphasisTypeBoldItalic">IDH1</span> <strong class="EmphasisTypeBold">and</strong> <span class="EmphasisTypeBoldItalic">IDH2</span> <strong class="EmphasisTypeBold">mutations and SNP 105C</strong> &gt; <strong class="EmphasisTypeBold">T in 189 AML patients</strong>
</p>
                      </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Gene</p></th><th align="left"><p xmlns="" class="SimplePara">Nucleotide change</p></th><th align="left"><p xmlns="" class="SimplePara">Amino acid change</p></th><th align="left"><p xmlns="" class="SimplePara">Number of patients</p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH1</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">CGT &gt; TGT</p></td><td align="left"><p xmlns="" class="SimplePara">R132C</p></td><td align="left"><p xmlns="" class="SimplePara">7</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH1</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">CGT &gt; CAT</p></td><td align="left"><p xmlns="" class="SimplePara">R132H</p></td><td align="left"><p xmlns="" class="SimplePara">6</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH1</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">CGT &gt; GGT</p></td><td align="left"><p xmlns="" class="SimplePara">R132G</p></td><td align="left"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH1</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">CGT &gt; CTT</p></td><td align="left"><p xmlns="" class="SimplePara">R132L</p></td><td align="left"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH2</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">CGG &gt; CAG</p></td><td align="left"><p xmlns="" class="SimplePara">R140Q</p></td><td align="left"><p xmlns="" class="SimplePara">20</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH2</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">CGG &gt; GGG</p></td><td align="left"><p xmlns="" class="SimplePara">R140G</p></td><td align="left"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH2</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">AGG &gt; AAG</p></td><td align="left"><p xmlns="" class="SimplePara">R172K</p></td><td align="left"><p xmlns="" class="SimplePara">5</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <em class="EmphasisTypeItalic">IDH1</em>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">GGC &gt; GGT</p></td><td align="left"><p xmlns="" class="SimplePara">G105G</p></td><td align="left"><p xmlns="" class="SimplePara">20</p></td></tr></tbody></table></div></figure>
<figure xmlns="" id="Tab2" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 2</span>
                        <p xmlns="" class="SimplePara">
                          <strong class="EmphasisTypeBold">Patient characteristics and distributions of</strong>
                          <span class="EmphasisTypeBoldItalic">IDH</span>
                          <strong class="EmphasisTypeBold">mutations for all patients and within groups</strong>
                        </p>
                      </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">CHARACTERISTIC</p></th><th align="center"><p xmlns="" class="SimplePara">All</p></th><th colspan="2" align="center"><p xmlns="" class="SimplePara">
<span class="EmphasisTypeBoldItalic">IDH1</span> codon 132:</p></th><th colspan="2" align="center"><p xmlns="" class="SimplePara">
<span class="EmphasisTypeBoldItalic">IDH1</span> codon 105 (synonymous SNP):</p></th><th colspan="2" align="center"><p xmlns="" class="SimplePara">
<span class="EmphasisTypeBoldItalic">IDH2</span> codon 140:</p></th><th colspan="2" align="center"><p xmlns="" class="SimplePara">
<span class="EmphasisTypeBoldItalic">IDH2</span> codon 172:</p></th></tr><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Total n = 189</p></th><th align="center">&nbsp;</th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Wild type</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Mutation</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Wild type</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Variant</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Wild type</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Mutation</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Wild type</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Mutation</span>
                            </p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Age median (range), years</p></td><td align="center"><p xmlns="" class="SimplePara">64 (19–88)</p></td><td align="center"><p xmlns="" class="SimplePara">63 (19–85)</p></td><td align="center"><p xmlns="" class="SimplePara">70 (30–88)<strong class="EmphasisTypeBold">*</strong>
</p></td><td align="center"><p xmlns="" class="SimplePara">64 (19–88)</p></td><td align="center"><p xmlns="" class="SimplePara">66 (29–84)</p></td><td align="center"><p xmlns="" class="SimplePara">63 (19–88)</p></td><td align="center"><p xmlns="" class="SimplePara">66 (37–83)<strong class="EmphasisTypeBold">*</strong>
</p></td><td align="center"><p xmlns="" class="SimplePara">64 (19–88)</p></td><td align="center"><p xmlns="" class="SimplePara">72 (46–74)<strong class="EmphasisTypeBold">*</strong>
</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Gender</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Male</p></td><td align="center"><p xmlns="" class="SimplePara">95</p></td><td align="center"><p xmlns="" class="SimplePara">90</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">85</p></td><td align="center"><p xmlns="" class="SimplePara">10</p></td><td align="center"><p xmlns="" class="SimplePara">85</p></td><td align="center"><p xmlns="" class="SimplePara">10</p></td><td align="center"><p xmlns="" class="SimplePara">92</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Female</p></td><td align="center"><p xmlns="" class="SimplePara">94</p></td><td align="center"><p xmlns="" class="SimplePara">84</p></td><td align="center"><p xmlns="" class="SimplePara">10</p></td><td align="center"><p xmlns="" class="SimplePara">84</p></td><td align="center"><p xmlns="" class="SimplePara">10</p></td><td align="center"><p xmlns="" class="SimplePara">83</p></td><td align="center"><p xmlns="" class="SimplePara">11</p></td><td align="center"><p xmlns="" class="SimplePara">92</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Karyotype</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Normal</p></td><td align="center"><p xmlns="" class="SimplePara">108</p></td><td align="center"><p xmlns="" class="SimplePara">99</p></td><td align="center"><p xmlns="" class="SimplePara">9</p></td><td align="center"><p xmlns="" class="SimplePara">95</p></td><td align="center"><p xmlns="" class="SimplePara">13</p></td><td align="center"><p xmlns="" class="SimplePara">96</p></td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">106</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Aberrant</p></td><td align="center"><p xmlns="" class="SimplePara">75</p></td><td align="center"><p xmlns="" class="SimplePara">69</p></td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center"><p xmlns="" class="SimplePara">68</p></td><td align="center"><p xmlns="" class="SimplePara">7</p></td><td align="center"><p xmlns="" class="SimplePara">66</p></td><td align="center"><p xmlns="" class="SimplePara">9</p></td><td align="center"><p xmlns="" class="SimplePara">72</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Missing data</p></td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Risk group</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Low</p></td><td align="center"><p xmlns="" class="SimplePara">32</p></td><td align="center"><p xmlns="" class="SimplePara">31</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center"><p xmlns="" class="SimplePara">30</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td><td align="center"><p xmlns="" class="SimplePara">29</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">31</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Intermediate</p></td><td align="center"><p xmlns="" class="SimplePara">87</p></td><td align="center"><p xmlns="" class="SimplePara">80</p></td><td align="center"><p xmlns="" class="SimplePara">7</p></td><td align="center"><p xmlns="" class="SimplePara">72</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">75</p></td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">86</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      High</p></td><td align="center"><p xmlns="" class="SimplePara">55</p></td><td align="center"><p xmlns="" class="SimplePara">51</p></td><td align="center"><p xmlns="" class="SimplePara">4</p></td><td align="center"><p xmlns="" class="SimplePara">52</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">51</p></td><td align="center"><p xmlns="" class="SimplePara">4</p></td><td align="center"><p xmlns="" class="SimplePara">52</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Missing data</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">13</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td><td align="center"><p xmlns="" class="SimplePara">14</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">FLT3 status</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      FLT3 wild type</p></td><td align="center"><p xmlns="" class="SimplePara">116</p></td><td align="center"><p xmlns="" class="SimplePara">109</p></td><td align="center"><p xmlns="" class="SimplePara">7</p></td><td align="center"><p xmlns="" class="SimplePara">104</p></td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">101</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">114</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      FLT3-ITD</p></td><td align="center"><p xmlns="" class="SimplePara">37</p></td><td align="center"><p xmlns="" class="SimplePara">34</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">32</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">33</p></td><td align="center"><p xmlns="" class="SimplePara">4</p></td><td align="center"><p xmlns="" class="SimplePara">36</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Missing data**</p></td><td align="center"><p xmlns="" class="SimplePara">36</p></td><td align="center"><p xmlns="" class="SimplePara">31</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">33</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">34</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td><td align="center"><p xmlns="" class="SimplePara">34</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      NPM1 status</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      NPM1 wild type</p></td><td align="center"><p xmlns="" class="SimplePara">99</p></td><td align="center"><p xmlns="" class="SimplePara">92</p></td><td align="center"><p xmlns="" class="SimplePara">7</p></td><td align="center"><p xmlns="" class="SimplePara">87</p></td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">88</p></td><td align="center"><p xmlns="" class="SimplePara">11</p></td><td align="center"><p xmlns="" class="SimplePara">96</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      NPM1 mutation</p></td><td align="center"><p xmlns="" class="SimplePara">52</p></td><td align="center"><p xmlns="" class="SimplePara">49</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">47</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">44</p></td><td align="center"><p xmlns="" class="SimplePara">8</p></td><td align="center"><p xmlns="" class="SimplePara">52</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Missing data**</p></td><td align="center"><p xmlns="" class="SimplePara">38</p></td><td align="center"><p xmlns="" class="SimplePara">33</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">35</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">36</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td><td align="center"><p xmlns="" class="SimplePara">36</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Induction treatment response</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Complete remission</p></td><td align="center"><p xmlns="" class="SimplePara">132</p></td><td align="center"><p xmlns="" class="SimplePara">122</p></td><td align="center"><p xmlns="" class="SimplePara">10</p></td><td align="center"><p xmlns="" class="SimplePara">119</p></td><td align="center"><p xmlns="" class="SimplePara">13</p></td><td align="center"><p xmlns="" class="SimplePara">119</p></td><td align="center"><p xmlns="" class="SimplePara">13</p></td><td align="center"><p xmlns="" class="SimplePara">127</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Not complete remission</p></td><td align="center"><p xmlns="" class="SimplePara">49</p></td><td align="center"><p xmlns="" class="SimplePara">44</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">43</p></td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center"><p xmlns="" class="SimplePara">43</p></td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center"><p xmlns="" class="SimplePara">49</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Missing information</p></td><td align="center"><p xmlns="" class="SimplePara">8</p></td><td align="center"><p xmlns="" class="SimplePara">8</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td><td align="center"><p xmlns="" class="SimplePara">7</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td><td align="center"><p xmlns="" class="SimplePara">8</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH1</em> codon 132</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">174</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">157</p></td><td align="center"><p xmlns="" class="SimplePara">17</p></td><td align="center"><p xmlns="" class="SimplePara">153</p></td><td align="center"><p xmlns="" class="SimplePara">21</p></td><td align="center"><p xmlns="" class="SimplePara">169</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Mutation</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH1</em> codon 105 (synonymous SNP)</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">169</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">151</p></td><td align="center"><p xmlns="" class="SimplePara">18</p></td><td align="center"><p xmlns="" class="SimplePara">165</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Variant</p></td><td align="center"><p xmlns="" class="SimplePara">20</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">17</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">19</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH2</em> codon 140</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">168</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">163</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Mutation</p></td><td align="center"><p xmlns="" class="SimplePara">21</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">21</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH2</em> codon 172</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">184</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">      Mutation</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                      <p xmlns="" class="SimplePara">*Mann–Whitney test for difference in age distribution between patients with <em class="EmphasisTypeItalic">IDH</em> mutation (<em class="EmphasisTypeItalic">IDH1</em> or <em class="EmphasisTypeItalic">IDH2</em>) and <em class="EmphasisTypeItalic">IDH</em> wildtype patients, median 62 vs 69&nbsp;years; p = 0.036.</p>
                      <p xmlns="" class="SimplePara">**<em class="EmphasisTypeItalic">FLT3</em>-ITD and <em class="EmphasisTypeItalic">NPM1</em> mutations were not routinely analyzed in all non-normal karyotype patients.</p>
                    </div></figure>
</div>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">No significant differences between <em xmlns="" class="EmphasisTypeItalic">IDH</em> genotype groups in terms of median age at diagnosis, gender, treatment regime, or distribution of <em xmlns="" class="EmphasisTypeItalic">FLT3/NPM1</em> mutations were found in the patient cohort. However, the median age at diagnosis appear to be higher in patients with mutated <em xmlns="" class="EmphasisTypeItalic">IDH</em> gene (<em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em>) than in patients with wild-type <em xmlns="" class="EmphasisTypeItalic">IDH</em> gene (69 vs. 62&nbsp;years, respectively, p = 0.036, Table&nbsp;
<span class="InternalRef"><a href="#Tab2">2</a></span>).</p>
              </section><section id="Sec4" class="Section2 RenderAsSection2">
                <h3 class="Heading">Impact of <em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em> mutations on treatment response and overall survival</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">We found no significant difference on OS for patients with <em xmlns="" class="EmphasisTypeItalic">IDH1</em> codon 132 mutations, neither in the entire group nor when stratified in different risk groups.</p>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene codon 140 revealed a significant increased risk for shorter OS in the whole patient group in relation to the wild type <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140, (HR = 1.94; 1.07-3.53; 95% confidence interval, p = 0.03) (Cox regression Table&nbsp;
<span class="InternalRef"><a href="#Tab3">3</a></span>; 15 patients with missing karyotype data where excluded from the analysis). This was most pronounced among the intermediate risk group patients with a median OS 6 <em xmlns="" class="EmphasisTypeItalic">vs.</em> 18&nbsp;months, for mutated and wild type patients, respectively, p = 0.001, (Figure&nbsp;
<span class="InternalRef"><a href="#Fig1">1</a></span>A; entire cohort presented in Figure&nbsp;
<span class="InternalRef"><a href="#Fig1">1</a></span>B). Patients with <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 172 mutations showed an improved survival in the entire patient group compared to patients with wild type <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 172 in cox regression analysis (HR = 0.22; 0.07-0.74; 95% confidence interval, p = 0.014) (Table&nbsp;
<span class="InternalRef"><a href="#Tab3">3</a></span>) and Kaplan Meier analysis, (p = 0.09, Figure&nbsp;
<span class="InternalRef"><a href="#Fig2">2</a></span>).<figure xmlns="" id="Tab3" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 3</span>
                        <p xmlns="" class="SimplePara">
                          <strong class="EmphasisTypeBold">Cox regression of overall survival, forced entry method</strong>
                        </p>
                      </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">Covariates</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">N</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">HR</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">95% CI</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">p</span>
                            </p></th></tr></thead><tbody><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Age</p></td><td align="center">&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">1.022</p></td><td align="center"><p xmlns="" class="SimplePara">1.002-1.042</p></td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">0.033</strong>
                            </p></td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Risk group</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Low risk</p></td><td align="center"><p xmlns="" class="SimplePara">32</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Intermediate risk</p></td><td align="center"><p xmlns="" class="SimplePara">87</p></td><td align="center"><p xmlns="" class="SimplePara">2.980</p></td><td align="center"><p xmlns="" class="SimplePara">1.495-5.942</p></td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">0.002</strong>
                            </p></td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">High risk</p></td><td align="center"><p xmlns="" class="SimplePara">55</p></td><td align="center"><p xmlns="" class="SimplePara">5.993</p></td><td align="center"><p xmlns="" class="SimplePara">2.912-12.333</p></td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">&lt;0.001</strong>
                            </p></td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Treatment</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Chemotherapy</p></td><td align="center"><p xmlns="" class="SimplePara">118</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Chemotherapy + allo-SCT</p></td><td align="center"><p xmlns="" class="SimplePara">56</p></td><td align="center"><p xmlns="" class="SimplePara">0.231</p></td><td align="center"><p xmlns="" class="SimplePara">0.118-0.450</p></td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">&lt;0.001</strong>
                            </p></td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH1</em> codon 132</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">162</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Mutated</p></td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">0.816</p></td><td align="center"><p xmlns="" class="SimplePara">0.390-1.708</p></td><td align="center"><p xmlns="" class="SimplePara">0.59</p></td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH2</em> codon 140</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">155</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Mutated</p></td><td align="center"><p xmlns="" class="SimplePara">19</p></td><td align="center"><p xmlns="" class="SimplePara">1.942</p></td><td align="center"><p xmlns="" class="SimplePara">1.068-3.530</p></td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">0.030</strong>
                            </p></td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH2</em> codon 172</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">169</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Mutated</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">0.222</p></td><td align="center"><p xmlns="" class="SimplePara">0.067-0.738</p></td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">0.014</strong>
                            </p></td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">
<em class="EmphasisTypeItalic">IDH1</em> SNP codon 105 GGC &gt; GGT</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Wild type</p></td><td align="center"><p xmlns="" class="SimplePara">154</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center">&nbsp;</td><td align="center">&nbsp;</td></tr><tr class="noclass"><td align="justify"><p xmlns="" class="SimplePara">Variant</p></td><td align="center"><p xmlns="" class="SimplePara">20</p></td><td align="center"><p xmlns="" class="SimplePara">1.496</p></td><td align="center"><p xmlns="" class="SimplePara">0.812-2.756</p></td><td align="center"><p xmlns="" class="SimplePara">0.196</p></td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                      <p xmlns="" class="SimplePara">95% CI = 95% Confidence interval; HR = Hazard ratio.</p>
                      <p xmlns="" class="SimplePara">Significant <em class="EmphasisTypeItalic">P</em>-values (<em class="EmphasisTypeItalic">P</em> &lt;0.05) in boldface.</p>
                    </div></figure>
<figure xmlns="" class="Figure" id="Fig1"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_Article_47_Fig1_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_Article_47_Fig1_HTML.jpg"></img></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 1</span>
                        <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Kaplan-Meier curves of OS,</strong> <span class="EmphasisTypeBoldItalic">IDH2</span> <strong class="EmphasisTypeBold">codon 140. (A)</strong> Significant differences in OS between <em class="EmphasisTypeItalic">IDH2</em> codon 140 genotypes in intermediate risk AML patients. Median OS 6 <em class="EmphasisTypeItalic">vs.</em> 18&nbsp;months (p &lt; 0.001) for <em class="EmphasisTypeItalic">IDH2</em> codon 140 mutated patients and wild-type patients, respectively. <strong class="EmphasisTypeBold">(B)</strong> OS for AML-patients with mutated or unmutated <em class="EmphasisTypeItalic">IDH2</em> codon 140 in the entire group, median OS 9 <em class="EmphasisTypeItalic">vs.</em> 14&nbsp;months, respectively (p = 0.278).</p>
                      </div></figcaption></figure>
<figure xmlns="" class="Figure" id="Fig2"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_Article_47_Fig2_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_Article_47_Fig2_HTML.jpg"></img></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 2</span>
                        <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Kaplan-Meier curve of OS,</strong> <span class="EmphasisTypeBoldItalic">IDH2</span> <strong class="EmphasisTypeBold">codon 172.</strong> The low frequency of AML-patients with mutated <em class="EmphasisTypeItalic">IDH2</em> codon 172 showed a tendency towards improved OS survival compared to wildtype <em class="EmphasisTypeItalic">IDH2</em>, OS 30 <em class="EmphasisTypeItalic">vs.</em> 12&nbsp;months, p = 0.09.</p>
                      </div></figcaption></figure>
</div>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">There were no significant differences in the distribution of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> genotypes among patients with CR and no CR.</p>
              </section><section id="Sec5" class="Section2 RenderAsSection2">
                <h3 class="Heading">The <em class="EmphasisTypeItalic">IDH1</em> SNP variant influences overall survival</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">All patients were successfully genotyped for <em xmlns="" class="EmphasisTypeItalic">IDH1</em> codon 105 SNP (<em xmlns="" class="EmphasisTypeItalic">rs11554137</em>) (Table&nbsp;
<span class="InternalRef"><a href="#Tab1">1</a></span>) that was not associated with the <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations (only 7 overlapping cases; 3 in <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and 4 in <em xmlns="" class="EmphasisTypeItalic">IDH2</em>). The synonymous SNP (GGC &gt; GGT) was found in 20 patients (10.6%) in the entire cohort. Kaplan Meier curves with log rank tests also revealed a significant difference in OS between the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> codon 105 SNP variants, where heterozygous carriers of the T allele displayed a shorter survival compared to patients with homozygous wild-type C alleles. This was significant only in the intermediate risk <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD negative AML patients. In this risk group, the median OS was 20 <em xmlns="" class="EmphasisTypeItalic">vs.</em> 6&nbsp;months for codon 105 wild-type C/C and variant T/C patients, respectively, (p = 0.004, Figure&nbsp;
<span class="InternalRef"><a href="#Fig3">3</a></span>). It should be noted that all the intermediate risk <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD negative patients with the codon 105&nbsp;T allele were also negative for <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations. However, in cox regression analysis the codon 105 SNP did not display independent significance due to other stronger factors affecting the outcome in the entire cohort (Table&nbsp;
<span class="InternalRef"><a href="#Tab3">3</a></span>).<figure xmlns="" class="Figure" id="Fig3"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_Article_47_Fig3_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_Article_47_Fig3_HTML.jpg"></img></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 3</span>
                        <p xmlns="" class="SimplePara">
<strong class="EmphasisTypeBold">Kaplan-Meier curve of OS,</strong> <span class="EmphasisTypeBoldItalic">IDH1</span> <strong class="EmphasisTypeBold">codon 105 SNP.</strong> Significant differences in OS between codon 105 genotypes in <em class="EmphasisTypeItalic">FLT3</em>-ITD negative intermediate risk patients; median OS 6 <em class="EmphasisTypeItalic">vs</em>. 20&nbsp;months (p = 0.004) for codon 105 variant allele and wild-type patients, respectively.</p>
                      </div></figcaption></figure>
</div>
              </section></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec6" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Discussion</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> genes in AML are reported as being associated to diverse outcomes by different groups
[<span class="CitationRef"><a href="#CR22" data-toggle="citation" data-target="CR22">22</a></span>]. Mardis <em xmlns="" class="EmphasisTypeItalic">et al</em>.
[<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>] was the first to identify mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene as a new recurrent mutation associated with CN-AML. Further, Marcucci <em xmlns="" class="EmphasisTypeItalic">et al</em>.
[<span class="CitationRef"><a href="#CR13" data-toggle="citation" data-target="CR13">13</a></span>] reported two different mutations in the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene (R140 and R172) in AML. In the present study we have investigated the frequency and impact of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations on outcome according to the different clinical risk groups, normal/aberrant cytogenetics, and also according to the <em xmlns="" class="EmphasisTypeItalic">FLT3</em> and <em xmlns="" class="EmphasisTypeItalic">NMP1</em> mutation status in 189 unselected AML patients. In our study cohort we found <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutated in 21.7% of the cases. <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were more common than <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations (13.8% vs 7.9%). The frequency of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations (7.9%) in our AML cohort is similar to previous reports of unselected AML patients (5.5%-10.4%)
[<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>, <span class="CitationRef"><a href="#CR14" data-toggle="citation" data-target="CR14">14</a></span>, <span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>–<span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>]. The <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations have been reported to have a prevalence of 6.1%-17.7% in unselected AML
[<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>, <span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>–<span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>], as compared to 13.8% in our study group. Investigation of the influence on OS in the entire study population (no selection in karyotypes, risk groups or <em xmlns="" class="EmphasisTypeItalic">FLT3/NPM1</em> status) for <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations conferred no significant difference compared to wild-type <em xmlns="" class="EmphasisTypeItalic">IDH1</em>, nor when statistical stratification was applied. In some studies, an influence on OS is seen with <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations for patients with CN-AML or intermediate risk group according to the <em xmlns="" class="EmphasisTypeItalic">FLT3/NPM1</em> status
[<span class="CitationRef"><a href="#CR13" data-toggle="citation" data-target="CR13">13</a></span>–<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>], while other groups could not detect any impact on survival with mutated <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene, which is in accordance with our results
[<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>, <span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>]. Furthermore, in our cohort we also found a slightly higher median age at diagnosis in patients with mutated <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene than in patients with wild type <em xmlns="" class="EmphasisTypeItalic">IDH1</em>. Our cohort covered a wide age span including both younger and older patients, but future studies investigating the impact of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations specifically in older AML patients could be warranted.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Two hotspot mutations are found in exon 4 in the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene, R140 and R172. In our cohort we found R140 to be altered with a frequency of 21/189 (11.1%) and R172 in 5/189 (2.6%) patients. We found prognostic significance on OS for the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140 mutations, where the intermediate risk patients with codon 140 mutations revealed a significantly shorter OS than codon 140 wildtype. <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 172 mutations were identified in a low frequency, only in 5 individuals, and were provided with a favorable outcome in our study cohort. However, Ward <em xmlns="" class="EmphasisTypeItalic">et al.</em> noted a trend toward improved survival for patients with <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140 mutations and also Green <em xmlns="" class="EmphasisTypeItalic">et al.</em> reported an unexpected favorable outcome associated with <em xmlns="" class="EmphasisTypeItalic">IDH2</em> R140 mutations and an unfavorable outcome for patients with <em xmlns="" class="EmphasisTypeItalic">IDH2</em> R172 mutation
[<span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>]. Patel <em xmlns="" class="EmphasisTypeItalic">et al.</em> also found a favorable effect for patients with mutant <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140
[<span class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>]. However, in the study of Green <em xmlns="" class="EmphasisTypeItalic">et al.</em>, there was a difference in patient median age at diagnosis compared to our study cohort, 43 vs. 64&nbsp;years respectively. In the study of Patel <em xmlns="" class="EmphasisTypeItalic">et al.</em> the patients’ median age at diagnosis also was much lower than in our cohort, 48 vs. 64&nbsp;years respectively. These may indicate that the effect of the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations is seen in elderly patients.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Figueroa <em xmlns="" class="EmphasisTypeItalic">et al.</em>
[<span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>] have shown that IDH mutant enzymes may result in a global DNA hypermethylation profile, blocking the cellular differentiation in hematopoietic cells through inhibition of demethylation of 5-metylcytosine (5-MeC) mediated via TET2. TET2 require α-KG for demethylation of 5-MeC and, other studies have demonstrated that the mutation dependent metabolite 2-HG is sufficient to promote leukemogenesis when mutated <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> convert α-KG to 2-HG
[<span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>]. The <em xmlns="" class="EmphasisTypeItalic">TET2</em> gene is also identified to be mutated in de novo AML (7-23%) and is mutually exclusive with <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations
[<span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The synonymous SNP 105C &gt; T, located in the same exon, but only overlapping in three cases, as R132 in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene, was also analyzed in our study. <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations simultaneously with the codon 105 variant were found in three patients with codon 140 mutation and in one case with codon 172 mutation. The frequency of the SNP was 20/189 (10.6%) in the entire cohort, and almost the same frequency (11.7%) has been reported among healthy volunteers by a German group
[<span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>]. The same group also reported this SNP to correlate to an inferior prognosis in CN-AML
[<span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>]. In accordance with this, we found a pronounced significant inferior overall survival in intermediate risk <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD negative patients carrying the variant codon 105 allele. The biologic effect of the silent SNP remains to be investigated in AML. One speculative explanation with a synonymous SNP is that it will cause a change in the rate of the protein translation resulting in affected protein folding and altered function of the protein
[<span class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>], or cause a new splicing site. Potentially the T variant enables a new splice site (GTGG[C/T]ACGG &gt; GTGgtacgg), resulting in a possible mRNA difference of 100&nbsp;bp. Calculation of splice-site scores by using the Analyzer Splice Tool (<span class="ExternalRef"><a href="http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm"><span class="RefSource">http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm</span></a></span>) would give a score of 72.5 to the potentially new splice site with the T variant compared with the natural splice site at the end of exon 4, which gives a score of 88.1. To test this possibly new splice site, we sequenced cDNA in three patients from this study with the SNP T allele, but the results provided no difference in sequence length between the C or T alleles, and thus no new splice variant was detected.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In summary, our results identified in total 21.7% <em xmlns="" class="EmphasisTypeItalic">IDH1/IDH2</em> mutations in the study population. Our results indicate that the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> codon 140 mutation have the highest potential as a prognostic marker, further stratifying intermediate risk patients.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In addition, the synonymous SNP 105C &gt; T in the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene may be a novel prognostic marker in AML of intermediate risk <em xmlns="" class="EmphasisTypeItalic">FLT3</em> negative patients however, this has to be confirmed through future studies. These markers may be especially useful in this heterogeneous group of AML patients, where other prognostic markers are absent and the outcomes vary widely. Further, studies have been carried out on possible new drugs by targeting the mutant IDH enzyme on leukemia cells, resulting in inhibition of accumulation of the 2-HG oncometabolite and subsequently differentiation of the AML blasts
[<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>, <span class="CitationRef"><a href="#CR34" data-toggle="citation" data-target="CR34">34</a></span>].</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec7" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Conclusions</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">
<em xmlns="" class="EmphasisTypeItalic">IDH</em> mutational status and/or <em xmlns="" class="EmphasisTypeItalic">IDH1</em> SNP 105C &gt; T variant may represent a new subgroup of AML patients and have the potential as tools for selecting patients expected to benefit the most from the new treatment alternatives.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec8" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Methods</h2><div class="js-CollapseSection"><section id="Sec9" class="Section2 RenderAsSection2">
                <h3 class="Heading">Patients</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">This study included 189 Swedish patients diagnosed with <em xmlns="" class="EmphasisTypeItalic">de novo</em> AML at Linköping University Hospital and Karolinska University Hospital in Huddinge between 1988 and 2010. The inclusion of the patients in this study was not consecutively included. Median age at diagnosis was 64&nbsp;years, range 19–88 years. Patient characteristics are summarized in Table&nbsp;
<span class="InternalRef"><a href="#Tab2">2</a></span>. Bone marrow or peripheral blood samples collected at diagnosis were used to isolate DNA for further genetic analysis. Risk group assignment at diagnosis was based on cytogenetic and molecular genetic findings as defined by ELN (European Leukemia Net)
[<span class="CitationRef"><a href="#CR35" data-toggle="citation" data-target="CR35">35</a></span>] and International Working Group recommendations
[<span class="CitationRef"><a href="#CR36" data-toggle="citation" data-target="CR36">36</a></span>], and other prognostic factors such as age, performance status and comorbidity, with minor modifications (see Swedish Hematology Association guidelines, <span class="ExternalRef"><a href="http://www.sfhem.se/Filarkiv/Nationella-riktlinjer"><span class="RefSource">http://www.sfhem.se/Filarkiv/Nationella-riktlinjer</span></a></span> accessed 2013-05-28). Swedish AML patients diagnosed in 2004 or later have been treated according to nationwide AML treatment guidelines (<span class="ExternalRef"><a href="http://www.sfhem.se/Filarkiv/Nationella-riktlinjer"><span class="RefSource">http://www.sfhem.se/Filarkiv/Nationella-riktlinjer</span></a></span>, accessed 2013-05-28). Thus, the majority of the patients received induction treatments including daunorubicin 60&nbsp;mg/m<sup>2</sup> once a day for three days combined with Cytarabine (AraC) as 1000&nbsp;mg/m<sup>2</sup> twice a day in 2&nbsp;h i.v. infusions for 5&nbsp;days. Before 2004, regional guidelines most commonly included AraC doses of 200&nbsp;mg/m<sup>2</sup> as 24&nbsp;h i.v. infusions for 7&nbsp;days combined with three days either daunorubicin or idarubicin
[<span class="CitationRef"><a href="#CR37" data-toggle="citation" data-target="CR37">37</a></span>]. Some patients also received other drugs in combination with daunorubicin/idarubicin and/or AraC, such as Mitoxantrone, Etoposide, 6-Thioguanine and Cladribine. For further treatment details, see Table&nbsp;
<span class="InternalRef"><a href="#Tab4">4</a></span>. Treatment response was evaluated as non-complete remission (no CR) or morphologic complete remission (CR)
[<span class="CitationRef"><a href="#CR36" data-toggle="citation" data-target="CR36">36</a></span>]. Patients treated by allogeneic stem cell transplantation (allo-SCT) (n = 59) were censored at the time of transplantation in the survival analysis. Informed consent was obtained from the patients and the study was approved by the local ethical committees and conducted in accordance with the Helsinki declaration.<figure xmlns="" id="Tab4" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 4</span>
                        <p xmlns="" class="SimplePara">
                          <strong class="EmphasisTypeBold">Induction treatment regimes</strong>
                        </p>
                      </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col align="left"></col><col align="left"></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Regime</p></th><th align="left"><p xmlns="" class="SimplePara">N (%)</p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Daunorubicine and Cytarabine (n = 116) or Daunorubicine, cytarabine and mitoxantrone (n = 2)</p></td><td align="left"><p xmlns="" class="SimplePara">118 (62.4)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Idarubicine and Cytarabine (n = 26) or Idarubicine, Cytarabine and Etoposide (n = 3)</p></td><td align="left"><p xmlns="" class="SimplePara">29 (15.3)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Idarubicine, Cytarabine and Cladribine</p></td><td align="left"><p xmlns="" class="SimplePara">20 (10.6)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Mitoxantrone, cytarabine and Etoposide (n = 7) or Mitoxantrone and Cytarabine (n = 2)</p></td><td align="left"><p xmlns="" class="SimplePara">9 (4.8)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Daunorubicine, Cytarabine and 6-Thioguanine</p></td><td align="left"><p xmlns="" class="SimplePara">8 (4.2)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Other/unknown<sup xmlns="http://www.w3.org/1999/xhtml">1</sup>
</p></td><td align="left"><p xmlns="" class="SimplePara">5 (2.6)</p></td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                      <p xmlns="" class="SimplePara">
<sup xmlns="http://www.w3.org/1999/xhtml">1</sup>Including 2 in clinical trial of combination therapy with Tipifarnib, and 1 with Fludarabine, Cytarabine and G-CSF. 2 patients with unknown treatment but known curative intent.</p>
                    </div></figure>
</div>
              </section><section id="Sec10" class="Section2 RenderAsSection2">
                <h3 class="Heading">
<em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em> genotyping analysis</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mononuclear cells from either peripheral blood or bone marrow were enriched by Ficoll-Paque density centrifugation at the time of diagnosis and genomic DNA was extracted. For <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> genotyping analysis, a PCR reaction was performed in a total volume of 20&nbsp;μl containing 10–50&nbsp;ng DNA, 0.5U Taq DNA polymerase, 2&nbsp;mM MgCl<sub>2,</sub> 0.2&nbsp;mM dNTPs, 1xPCR buffer, 1&nbsp;μM each of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> forward primer (5’ctcagagccttcgctttctg) and reverse primer (5’cacatacaagttggaaatttctgg) and of <em xmlns="" class="EmphasisTypeItalic">IDH2</em> forward primer (5’ggggttcaaattctggttga) and reverse primer (5’ctaggcgaggagctccagt). The terminal cycling conditions for both <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> were an initial denaturation at 94°C for 2&nbsp;min followed by 35&nbsp;cycles at 94°C for 30&nbsp;s, 55°C for 30&nbsp;s, 72°C for 30&nbsp;s and an end extension at 72°C for 5&nbsp;min. The PCR product was purified by using ExoSAP-IT and direct sequencing was performed by using BigDye Terminator v3.1 Cycle Sequencing Kit (AB Applied Biosystems). The <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> sequences were compared to the wild type <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> to detect the genetic variations (NM_005896.2 and NM_002168.2 respectively).</p>
              </section><section id="Sec11" class="Section2 RenderAsSection2">
                <h3 class="Heading">Statistical analysis</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Fisher’s exact test was used to compare differences in genotype distribution between patients with CR and no CR. Mann Whitney Test or Fisher’s exact test was used to investigate differences between genotype groups in terms of age, gender and karyotype distributions, or other characteristics. Kaplan Meier survival analysis with log rank test for significance was used to evaluate the impact of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> genotype on overall survival (OS) (calculated as time from diagnosis until death, date of the latest follow-up, or date of allo-SCT). Multivariable survival analysis was conducted using Cox regression with a forced entry method, taking age, risk group, treatment, <em xmlns="" class="EmphasisTypeItalic">IDH1/2</em> mutations and <em xmlns="" class="EmphasisTypeItalic">IDH1</em> SNP105 genotype into account. The impact of <em xmlns="" class="EmphasisTypeItalic">IDH</em> genotype was evaluated in the entire patient material and in subgroups stratified by risk group and <em xmlns="" class="EmphasisTypeItalic">FLT3</em> status. A p-value of 0.05 was considered significant, and all analyses were performed using IBM SPSS Statistics v.20.</p>
              </section></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec12" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Authors’ information</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Kourosh Lotfi and Peter Söderkvist share last authorship.</p></div></section>
          <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="Declarations"><h2 class="Heading js-ToggleCollapseSection">
              Declarations
            </h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Acknowledgments"><h3 xmlns="" class="Heading">Acknowledgements</h3><p xmlns="" class="SimplePara">This work was supported by grants from the Swedish Cancer Society, the County Council of Östergötland, AFA Insurance, Stockholm Cancer Society, Karolinska Institutet, and the Swedish Research Council. The authors thank Annette Molbaek, Åsa Schippert and Jenny Welander for advice and technical assistance. We would also like to thank Christer Paul, Hareth Nahi and Sofia Bengtzén, Karolinska Institutet, for help with sample collection, clinical data, and technical assistance.</p></div><aside class="Appendix" id="App1">
              
                <h3 class="Heading">Authors' original submitted files for images</h3><div id="widgetContainer"></div>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Below are the links to the authors’ original submitted files for images.<div class="MediaObject" id="MOESM1">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_47_MOESM1_ESM.tiff">40364_2014_47_MOESM1_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Authors’ original file for figure 1</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM2">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_47_MOESM2_ESM.tiff">40364_2014_47_MOESM2_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Authors’ original file for figure 2</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM3">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_47_MOESM3_ESM.tiff">40364_2014_47_MOESM3_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Authors’ original file for figure 3</span>
                        </div></div>
                  </div>
<div class="MediaObject" id="MOESM4">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F2050-7771-2-18/MediaObjects/40364_2014_47_MOESM4_ESM.tiff">40364_2014_47_MOESM4_ESM.tiff</a>
                          <span xmlns="" class="SimplePara">Authors’ original file for figure 4</span>
                        </div></div>
                  </div>
</div>
              
            </aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Competing interests</h3><p xmlns="" class="SimplePara">The authors declare that they have no competing interests.</p></aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Authors’ contributions</h3><p xmlns="" class="SimplePara">K.W: Research, laboratory work, data compilation, manuscript writing; IJF: Resarch, clinical data compilation and statistical analysis, manuscript writing; R.C: Clinical data compilation and consultation; E.P: Patient material and clinical data collection; M.H: <em class="EmphasisTypeItalic">FLT3</em>/<em class="EmphasisTypeItalic">NPM1</em> analysis, data collection; H.G: Data and statistical analysis; K.L: Research, patient material and clinical data collection; P.S: Conception and study design, research. All authors critically reviewed the manuscript. All authors read and approved the final manuscript.</p></aside></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 Affiliations" id="Aff"><h2 class="Heading js-ToggleCollapseSection">Authors’ Affiliations</h2><div class="js-CollapseSection"><div class="Affiliation" id="Aff1"><span class="AffiliationNumber">(1)</span><div class="AffiliationText">Department of Clinical and Experimental Medicine, Linköping University</div></div><div class="Affiliation" id="Aff2"><span class="AffiliationNumber">(2)</span><div class="AffiliationText">Department of Medical and Health Sciences, Linköping University</div></div><div class="Affiliation" id="Aff3"><span class="AffiliationNumber">(3)</span><div class="AffiliationText">Department of Hematology, County Council of Östergötland</div></div><div class="Affiliation" id="Aff4"><span class="AffiliationNumber">(4)</span><div class="AffiliationText">Division of Hematology, Department of Medicine, Karolinska Institutet</div></div><div class="Affiliation" id="Aff5"><span class="AffiliationNumber">(5)</span><div class="AffiliationText">Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University</div></div><div class="Affiliation" id="Aff6"><span class="AffiliationNumber">(6)</span><div class="AffiliationText">Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine</div></div><div class="Affiliation" id="Aff7"><span class="AffiliationNumber">(7)</span><div class="AffiliationText">Department of Clinical Genetics, County Council of Östergötland</div></div></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 SectionTypeMaterialsAndMethods" id="Bib1"><h2 class="Heading js-ToggleCollapseSection">References</h2><div class="js-CollapseSection"><ol class="BibliographyWrapper"><li class="Citation"><cite class="CitationContent" id="CR1">Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A: <strong class="EmphasisTypeBold">The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties.</strong> <em class="EmphasisTypeItalic">Blood</em> 1998, <strong class="EmphasisTypeBold">92:</strong> 2322–2333.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9746770"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20importance%20of%20diagnostic%20cytogenetics%20on%20outcome%20in%20AML%3A%20analysis%20of%201%2C612%20patients%20entered%20into%20the%20MRC%20AML%2010%20trial.%20The%20Medical%20Research%20Council%20Adult%20and%20Children%E2%80%99s%20Leukaemia%20Working%20Parties&amp;author=D.%20Grimwade&amp;author=H.%20Walker&amp;author=F.%20Oliver&amp;author=K.%20Wheatley&amp;author=C.%20Harrison&amp;author=G.%20Harrison&amp;author=J.%20Rees&amp;author=I.%20Hann&amp;author=R.%20Stevens&amp;author=A.%20Burnett&amp;author=A.%20Goldstone&amp;journal=Blood&amp;volume=92&amp;pages=2322-2333&amp;publication_year=1998"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR2">Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH: <strong class="EmphasisTypeBold">The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.</strong> <em class="EmphasisTypeItalic">Blood</em> 2001, <strong class="EmphasisTypeBold">98:</strong> 1312–1320. 10.1182/blood.V98.5.1312<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11520776"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood.V98.5.1312"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20predictive%20value%20of%20hierarchical%20cytogenetic%20classification%20in%20older%20adults%20with%20acute%20myeloid%20leukemia%20%28AML%29%3A%20analysis%20of%201065%20patients%20entered%20into%20the%20United%20Kingdom%20Medical%20Research%20Council%20AML11%20trial&amp;author=D.%20Grimwade&amp;author=H.%20Walker&amp;author=G.%20Harrison&amp;author=F.%20Oliver&amp;author=S.%20Chatters&amp;author=CJ.%20Harrison&amp;author=K.%20Wheatley&amp;author=AK.%20Burnett&amp;author=AH.%20Goldstone&amp;journal=Blood&amp;volume=98&amp;pages=1312-1320&amp;publication_year=2001&amp;doi=10.1182%2Fblood.V98.5.1312"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR3">Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S: <strong class="EmphasisTypeBold">Implications of NRAS mutations in AML: a study of 2502 patients.</strong> <em class="EmphasisTypeItalic">Blood</em> 2006, <strong class="EmphasisTypeBold">107:</strong> 3847–3853. 10.1182/blood-2005-08-3522<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16434492"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2005-08-3522"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Implications%20of%20NRAS%20mutations%20in%20AML%3A%20a%20study%20of%202502%20patients&amp;author=U.%20Bacher&amp;author=T.%20Haferlach&amp;author=C.%20Schoch&amp;author=W.%20Kern&amp;author=S.%20Schnittger&amp;journal=Blood&amp;volume=107&amp;pages=3847-3853&amp;publication_year=2006&amp;doi=10.1182%2Fblood-2005-08-3522"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR4">Stone RM: <strong class="EmphasisTypeBold">The difficult problem of acute myeloid leukemia in the older adult.</strong> <em class="EmphasisTypeItalic">CA Cancer J Clin</em> 2002, <strong class="EmphasisTypeBold">52:</strong> 363–371. 10.3322/canjclin.52.6.363<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12469764"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.3322/canjclin.52.6.363"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20difficult%20problem%20of%20acute%20myeloid%20leukemia%20in%20the%20older%20adult&amp;author=RM.%20Stone&amp;journal=CA%20Cancer%20J%20Clin&amp;volume=52&amp;pages=363-371&amp;publication_year=2002&amp;doi=10.3322%2Fcanjclin.52.6.363"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR5">Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF: <strong class="EmphasisTypeBold">Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</strong> <em class="EmphasisTypeItalic">N Engl J Med</em> 2005, <strong class="EmphasisTypeBold">352:</strong> 254–266. 10.1056/NEJMoa041974<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15659725"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1056/NEJMoa041974"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cytoplasmic%20nucleophosmin%20in%20acute%20myelogenous%20leukemia%20with%20a%20normal%20karyotype&amp;author=B.%20Falini&amp;author=C.%20Mecucci&amp;author=E.%20Tiacci&amp;author=M.%20Alcalay&amp;author=R.%20Rosati&amp;author=L.%20Pasqualucci&amp;author=R.%20La%20Starza&amp;author=D.%20Diverio&amp;author=E.%20Colombo&amp;author=A.%20Santucci&amp;author=B.%20Bigerna&amp;author=R.%20Pacini&amp;author=A.%20Pucciarini&amp;author=A.%20Liso&amp;author=M.%20Vignetti&amp;author=P.%20Fazi&amp;author=N.%20Meani&amp;author=V.%20Pettirossi&amp;author=G.%20Saglio&amp;author=F.%20Mandelli&amp;author=F.%20Lo-Coco&amp;author=PG.%20Pelicci&amp;author=MF.%20Martelli&amp;journal=N%20Engl%20J%20Med&amp;volume=352&amp;pages=254-266&amp;publication_year=2005&amp;doi=10.1056%2FNEJMoa041974"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR6">Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T: <strong class="EmphasisTypeBold">Risk assessment in patients with acute myeloid leukemia and a normal karyotype.</strong> <em class="EmphasisTypeItalic">Clin Cancer Res</em> 2005, <strong class="EmphasisTypeBold">11:</strong> 1416–1424. 10.1158/1078-0432.CCR-04-1552<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15746041"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1158/1078-0432.CCR-04-1552"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Risk%20assessment%20in%20patients%20with%20acute%20myeloid%20leukemia%20and%20a%20normal%20karyotype&amp;author=M.%20Bienz&amp;author=M.%20Ludwig&amp;author=EO.%20Leibundgut&amp;author=BU.%20Mueller&amp;author=D.%20Ratschiller&amp;author=M.%20Solenthaler&amp;author=MF.%20Fey&amp;author=T.%20Pabst&amp;journal=Clin%20Cancer%20Res&amp;volume=11&amp;pages=1416-1424&amp;publication_year=2005&amp;doi=10.1158%2F1078-0432.CCR-04-1552"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR7">Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S: <strong class="EmphasisTypeBold">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.</strong> <em class="EmphasisTypeItalic">Leukemia</em> 1996, <strong class="EmphasisTypeBold">10:</strong> 1911–1918.<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8946930"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Internal%20tandem%20duplication%20of%20the%20flt3%20gene%20found%20in%20acute%20myeloid%20leukemia&amp;author=M.%20Nakao&amp;author=S.%20Yokota&amp;author=T.%20Iwai&amp;author=H.%20Kaneko&amp;author=S.%20Horiike&amp;author=K.%20Kashima&amp;author=Y.%20Sonoda&amp;author=T.%20Fujimoto&amp;author=S.%20Misawa&amp;journal=Leukemia&amp;volume=10&amp;pages=1911-1918&amp;publication_year=1996"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR8">Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD: <strong class="EmphasisTypeBold">Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?</strong> <em class="EmphasisTypeItalic">Blood</em> 2007, <strong class="EmphasisTypeBold">109:</strong> 431–448. 10.1182/blood-2006-06-001149<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785102"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16960150"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2006-06-001149"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Clinical%20relevance%20of%20mutations%20and%20gene-expression%20changes%20in%20adult%20acute%20myeloid%20leukemia%20with%20normal%20cytogenetics%3A%20are%20we%20ready%20for%20a%20prognostically%20prioritized%20molecular%20classification%3F&amp;author=K.%20Mrozek&amp;author=G.%20Marcucci&amp;author=P.%20Paschka&amp;author=SP.%20Whitman&amp;author=CD.%20Bloomfield&amp;journal=Blood&amp;volume=109&amp;pages=431-448&amp;publication_year=2007&amp;doi=10.1182%2Fblood-2006-06-001149"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR9">Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, <em class="EmphasisTypeItalic">et al</em>.: <strong class="EmphasisTypeBold">Recurring mutations found by sequencing an acute myeloid leukemia genome.</strong> <em class="EmphasisTypeItalic">N Engl J Med</em> 2009, <strong class="EmphasisTypeBold">361:</strong> 1058–1066. 10.1056/NEJMoa0903840<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201812"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19657110"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1056/NEJMoa0903840"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Recurring%20mutations%20found%20by%20sequencing%20an%20acute%20myeloid%20leukemia%20genome&amp;author=ER.%20Mardis&amp;author=L.%20Ding&amp;author=DJ.%20Dooling&amp;author=DE.%20Larson&amp;author=MD.%20McLellan&amp;author=K.%20Chen&amp;author=DC.%20Koboldt&amp;author=RS.%20Fulton&amp;author=KD.%20Delehaunty&amp;author=SD.%20McGrath&amp;author=LA.%20Fulton&amp;author=DP.%20Locke&amp;author=VJ.%20Magrini&amp;author=RM.%20Abbott&amp;author=TL.%20Vickery&amp;author=JS.%20Reed&amp;author=JS.%20Robinson&amp;author=T.%20Wylie&amp;author=SM.%20Smith&amp;author=L.%20Carmichael&amp;author=JM.%20Eldred&amp;author=CC.%20Harris&amp;author=J.%20Walker&amp;author=JB.%20Peck&amp;author=F.%20Du&amp;author=AF.%20Dukes&amp;author=GE.%20Sanderson&amp;author=AM.%20Brummett&amp;author=E.%20Clark&amp;author=JF.%20McMichael&amp;journal=N%20Engl%20J%20Med&amp;volume=361&amp;pages=1058-1066&amp;publication_year=2009&amp;doi=10.1056%2FNEJMoa0903840"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR10">Dang L, Jin S, Su SM: <strong class="EmphasisTypeBold">IDH mutations in glioma and acute myeloid leukemia.</strong> <em class="EmphasisTypeItalic">Trends Mol Med</em> 2010, <strong class="EmphasisTypeBold">16:</strong> 387–397. 10.1016/j.molmed.2010.07.002<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20692206"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.molmed.2010.07.002"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH%20mutations%20in%20glioma%20and%20acute%20myeloid%20leukemia&amp;author=L.%20Dang&amp;author=S.%20Jin&amp;author=SM.%20Su&amp;journal=Trends%20Mol%20Med&amp;volume=16&amp;pages=387-397&amp;publication_year=2010&amp;doi=10.1016%2Fj.molmed.2010.07.002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR11">Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY: <strong class="EmphasisTypeBold">Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.</strong> <em class="EmphasisTypeItalic">J Clin Oncol</em> 2009, <strong class="EmphasisTypeBold">27:</strong> 4150–4154. 10.1200/JCO.2009.21.9832<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19636000"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2009.21.9832"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Isocitrate%20dehydrogenase%201%20codon%20132%20mutation%20is%20an%20important%20prognostic%20biomarker%20in%20gliomas&amp;author=M.%20Sanson&amp;author=Y.%20Marie&amp;author=S.%20Paris&amp;author=A.%20Idbaih&amp;author=J.%20Laffaire&amp;author=F.%20Ducray&amp;author=S.%20El%20Hallani&amp;author=B.%20Boisselier&amp;author=K.%20Mokhtari&amp;author=K.%20Hoang-Xuan&amp;author=JY.%20Delattre&amp;journal=J%20Clin%20Oncol&amp;volume=27&amp;pages=4150-4154&amp;publication_year=2009&amp;doi=10.1200%2FJCO.2009.21.9832"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR12">Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: <strong class="EmphasisTypeBold">IDH1 and IDH2 mutations in gliomas.</strong> <em class="EmphasisTypeItalic">N Engl J Med</em> 2009, <strong class="EmphasisTypeBold">360:</strong> 765–773. 10.1056/NEJMoa0808710<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820383"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19228619"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1056/NEJMoa0808710"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutations%20in%20gliomas&amp;author=H.%20Yan&amp;author=DW.%20Parsons&amp;author=G.%20Jin&amp;author=R.%20McLendon&amp;author=BA.%20Rasheed&amp;author=W.%20Yuan&amp;author=I.%20Kos&amp;author=I.%20Batinic-Haberle&amp;author=S.%20Jones&amp;author=GJ.%20Riggins&amp;author=H.%20Friedman&amp;author=A.%20Friedman&amp;author=D.%20Reardon&amp;author=J.%20Herndon&amp;author=KW.%20Kinzler&amp;author=VE.%20Velculescu&amp;author=B.%20Vogelstein&amp;author=DD.%20Bigner&amp;journal=N%20Engl%20J%20Med&amp;volume=360&amp;pages=765-773&amp;publication_year=2009&amp;doi=10.1056%2FNEJMoa0808710"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR13">Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD: <strong class="EmphasisTypeBold">IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.</strong> <em class="EmphasisTypeItalic">J Clin Oncol</em> 2010, <strong class="EmphasisTypeBold">28:</strong> 2348–2355. 10.1200/JCO.2009.27.3730<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881719"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20368543"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2009.27.3730"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20gene%20mutations%20identify%20novel%20molecular%20subsets%20within%20de%20novo%20cytogenetically%20normal%20acute%20myeloid%20leukemia%3A%20a%20Cancer%20and%20Leukemia%20Group%20B%20study&amp;author=G.%20Marcucci&amp;author=K.%20Maharry&amp;author=YZ.%20Wu&amp;author=MD.%20Radmacher&amp;author=K.%20Mrozek&amp;author=D.%20Margeson&amp;author=KB.%20Holland&amp;author=SP.%20Whitman&amp;author=H.%20Becker&amp;author=S.%20Schwind&amp;author=KH.%20Metzeler&amp;author=BL.%20Powell&amp;author=TH.%20Carter&amp;author=JE.%20Kolitz&amp;author=M.%20Wetzler&amp;author=AJ.%20Carroll&amp;author=MR.%20Baer&amp;author=MA.%20Caligiuri&amp;author=RA.%20Larson&amp;author=CD.%20Bloomfield&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=2348-2355&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2009.27.3730"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR14">Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C: <strong class="EmphasisTypeBold">Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.</strong> <em class="EmphasisTypeItalic">J Clin Oncol</em> 2010, <strong class="EmphasisTypeBold">28:</strong> 3717–3723. 10.1200/JCO.2010.28.2285<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20625116"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2010.28.2285"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20impact%20of%20isocitrate%20dehydrogenase%20enzyme%20isoforms%201%20and%202%20mutations%20in%20acute%20myeloid%20leukemia%3A%20a%20study%20by%20the%20Acute%20Leukemia%20French%20Association%20group&amp;author=N.%20Boissel&amp;author=O.%20Nibourel&amp;author=A.%20Renneville&amp;author=C.%20Gardin&amp;author=O.%20Reman&amp;author=N.%20Contentin&amp;author=D.%20Bordessoule&amp;author=C.%20Pautas&amp;author=T.%20de%20Revel&amp;author=B.%20Quesnel&amp;author=P.%20Huchette&amp;author=N.%20Philippe&amp;author=S.%20Geffroy&amp;author=C.%20Terre&amp;author=X.%20Thomas&amp;author=S.%20Castaigne&amp;author=H.%20Dombret&amp;author=C.%20Preudhomme&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=3717-3723&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2010.28.2285"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR15">Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K, Horst HA, Germing U, Döhner H, Döhner K: <strong class="EmphasisTypeBold">IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.</strong> <em class="EmphasisTypeItalic">J Clin Oncol</em> 2010, <strong class="EmphasisTypeBold">28:</strong> 3636–3643. 10.1200/JCO.2010.28.3762<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20567020"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2010.28.3762"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutations%20are%20frequent%20genetic%20alterations%20in%20acute%20myeloid%20leukemia%20and%20confer%20adverse%20prognosis%20in%20cytogenetically%20normal%20acute%20myeloid%20leukemia%20with%20NPM1%20mutation%20without%20FLT3%20internal%20tandem%20duplication&amp;author=P.%20Paschka&amp;author=RF.%20Schlenk&amp;author=VI.%20Gaidzik&amp;author=M.%20Habdank&amp;author=J.%20Kronke&amp;author=L.%20Bullinger&amp;author=D.%20Spath&amp;author=S.%20Kayser&amp;author=M.%20Zucknick&amp;author=K.%20Gotze&amp;author=HA.%20Horst&amp;author=U.%20Germing&amp;author=H.%20D%C3%B6hner&amp;author=K.%20D%C3%B6hner&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=3636-3643&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2010.28.3762"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR16">Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM: <strong class="EmphasisTypeBold">Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.</strong> <em class="EmphasisTypeItalic">Nature</em> 2009, <strong class="EmphasisTypeBold">462:</strong> 739–744. 10.1038/nature08617<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818760"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19935646"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/nature08617"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cancer-associated%20IDH1%20mutations%20produce%202-hydroxyglutarate&amp;author=L.%20Dang&amp;author=DW.%20White&amp;author=S.%20Gross&amp;author=BD.%20Bennett&amp;author=MA.%20Bittinger&amp;author=EM.%20Driggers&amp;author=VR.%20Fantin&amp;author=HG.%20Jang&amp;author=S.%20Jin&amp;author=MC.%20Keenan&amp;author=KM.%20Marks&amp;author=RM.%20Prins&amp;author=PS.%20Ward&amp;author=KE.%20Yen&amp;author=LM.%20Liau&amp;author=JD.%20Rabinowitz&amp;author=LC.%20Cantley&amp;author=CB.%20Thompson&amp;author=MG.%20Vander%20Heiden&amp;author=SM.%20Su&amp;journal=Nature&amp;volume=462&amp;pages=739-744&amp;publication_year=2009&amp;doi=10.1038%2Fnature08617"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR17">Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB: <strong class="EmphasisTypeBold">The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.</strong> <em class="EmphasisTypeItalic">Cancer Cell</em> 2010, <strong class="EmphasisTypeBold">17:</strong> 225–234. 10.1016/j.ccr.2010.01.020<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849316"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20171147"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.01.020"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20common%20feature%20of%20leukemia-associated%20IDH1%20and%20IDH2%20mutations%20is%20a%20neomorphic%20enzyme%20activity%20converting%20alpha-ketoglutarate%20to%202-hydroxyglutarate&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=DR.%20Wise&amp;author=O.%20Abdel-Wahab&amp;author=BD.%20Bennett&amp;author=HA.%20Coller&amp;author=JR.%20Cross&amp;author=VR.%20Fantin&amp;author=CV.%20Hedvat&amp;author=AE.%20Perl&amp;author=JD.%20Rabinowitz&amp;author=M.%20Carroll&amp;author=SM.%20Su&amp;author=KA.%20Sharp&amp;author=RL.%20Levine&amp;author=CB.%20Thompson&amp;journal=Cancer%20Cell&amp;volume=17&amp;pages=225-234&amp;publication_year=2010&amp;doi=10.1016%2Fj.ccr.2010.01.020"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR18">Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A: <strong class="EmphasisTypeBold">Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.</strong> <em class="EmphasisTypeItalic">Cancer Cell</em> 2010, <strong class="EmphasisTypeBold">18:</strong> 553–567. 10.1016/j.ccr.2010.11.015<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105845"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21130701"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.11.015"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Leukemic%20IDH1%20and%20IDH2%20mutations%20result%20in%20a%20hypermethylation%20phenotype%2C%20disrupt%20TET2%20function%2C%20and%20impair%20hematopoietic%20differentiation&amp;author=ME.%20Figueroa&amp;author=O.%20Abdel-Wahab&amp;author=C.%20Lu&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=A.%20Shih&amp;author=Y.%20Li&amp;author=N.%20Bhagwat&amp;author=A.%20Vasanthakumar&amp;author=HF.%20Fernandez&amp;author=MS.%20Tallman&amp;author=Z.%20Sun&amp;author=K.%20Wolniak&amp;author=JK.%20Peeters&amp;author=W.%20Liu&amp;author=SE.%20Choe&amp;author=VR.%20Fantin&amp;author=E.%20Paietta&amp;author=B.%20L%C3%B6wenberg&amp;author=JD.%20Licht&amp;author=LA.%20Godley&amp;author=R.%20Delwel&amp;author=PJ.%20Valk&amp;author=CB.%20Thompson&amp;author=RL.%20Levine&amp;author=A.%20Melnick&amp;journal=Cancer%20Cell&amp;volume=18&amp;pages=553-567&amp;publication_year=2010&amp;doi=10.1016%2Fj.ccr.2010.11.015"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR19">Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y: <strong class="EmphasisTypeBold">Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases.</strong> <em class="EmphasisTypeItalic">Cancer Cell</em> 2011, <strong class="EmphasisTypeBold">19:</strong> 17–30. 10.1016/j.ccr.2010.12.014<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229304"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21251613"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.12.014"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Oncometabolite%202-hydroxyglutarate%20is%20a%20competitive%20inhibitor%20of%20alpha-ketoglutarate-dependent%20dioxygenases&amp;author=W.%20Xu&amp;author=H.%20Yang&amp;author=Y.%20Liu&amp;author=Y.%20Yang&amp;author=P.%20Wang&amp;author=SH.%20Kim&amp;author=S.%20Ito&amp;author=C.%20Yang&amp;author=MT.%20Xiao&amp;author=LX.%20Liu&amp;author=WQ.%20Jiang&amp;author=J.%20Liu&amp;author=JY.%20Zhang&amp;author=B.%20Wang&amp;author=S.%20Frye&amp;author=Y.%20Zhang&amp;author=YH.%20Xu&amp;author=QY.%20Lei&amp;author=KL.%20Guan&amp;author=SM.%20Zhao&amp;author=Y.%20Xiong&amp;journal=Cancer%20Cell&amp;volume=19&amp;pages=17-30&amp;publication_year=2011&amp;doi=10.1016%2Fj.ccr.2010.12.014"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR20">Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J: <strong class="EmphasisTypeBold">Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.</strong> <em class="EmphasisTypeItalic">J Clin Oncol</em> 2010, <strong class="EmphasisTypeBold">28:</strong> 2356–2364. 10.1200/JCO.2009.27.6899<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20368538"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2009.27.6899"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Impact%20of%20IDH1%20R132%20mutations%20and%20an%20IDH1%20single%20nucleotide%20polymorphism%20in%20cytogenetically%20normal%20acute%20myeloid%20leukemia%3A%20SNP%20rs11554137%20is%20an%20adverse%20prognostic%20factor&amp;author=K.%20Wagner&amp;author=F.%20Damm&amp;author=G.%20Gohring&amp;author=K.%20Gorlich&amp;author=M.%20Heuser&amp;author=I.%20Schafer&amp;author=O.%20Ottmann&amp;author=M.%20Lubbert&amp;author=W.%20Heit&amp;author=L.%20Kanz&amp;author=G.%20Schlimok&amp;author=AA.%20Raghavachar&amp;author=W.%20Fiedler&amp;author=HH.%20Kirchner&amp;author=W.%20Brugger&amp;author=M.%20Zucknick&amp;author=B.%20Schlegelberger&amp;author=G.%20Heil&amp;author=A.%20Ganser&amp;author=J.%20Krauter&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=2356-2364&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2009.27.6899"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR21">Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S: <strong class="EmphasisTypeBold">Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children’s Oncology Group and SWOG.</strong> <em class="EmphasisTypeItalic">Blood</em> 2011, <strong class="EmphasisTypeBold">118:</strong> 4561–4566. 10.1182/blood-2011-04-348888<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208275"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21873548"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2011-04-348888"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20implications%20of%20the%20IDH1%20synonymous%20SNP%20rs11554137%20in%20pediatric%20and%20adult%20AML%3A%20a%20report%20from%20the%20Children%E2%80%99s%20Oncology%20Group%20and%20SWOG&amp;author=PA.%20Ho&amp;author=KJ.%20Kopecky&amp;author=TA.%20Alonzo&amp;author=RB.%20Gerbing&amp;author=KL.%20Miller&amp;author=J.%20Kuhn&amp;author=R.%20Zeng&amp;author=RE.%20Ries&amp;author=SC.%20Raimondi&amp;author=BA.%20Hirsch&amp;author=V.%20Oehler&amp;author=CA.%20Hurwitz&amp;author=JL.%20Franklin&amp;author=AS.%20Gamis&amp;author=SH.%20Petersdorf&amp;author=JE.%20Anderson&amp;author=JE.%20Godwin&amp;author=GH.%20Reaman&amp;author=CL.%20Willman&amp;author=ID.%20Bernstein&amp;author=JP.%20Radich&amp;author=FR.%20Appelbaum&amp;author=DL.%20Stirewalt&amp;author=S.%20Meshinchi&amp;journal=Blood&amp;volume=118&amp;pages=4561-4566&amp;publication_year=2011&amp;doi=10.1182%2Fblood-2011-04-348888"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR22">Rakheja D, Konoplev S, Medeiros LJ, Chen W: <strong class="EmphasisTypeBold">IDH mutations in acute myeloid leukemia.</strong> <em class="EmphasisTypeItalic">Hum Pathol</em> 2012, <strong class="EmphasisTypeBold">43:</strong> 1541–1551. 10.1016/j.humpath.2012.05.003<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22917530"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.humpath.2012.05.003"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH%20mutations%20in%20acute%20myeloid%20leukemia&amp;author=D.%20Rakheja&amp;author=S.%20Konoplev&amp;author=LJ.%20Medeiros&amp;author=W.%20Chen&amp;journal=Hum%20Pathol&amp;volume=43&amp;pages=1541-1551&amp;publication_year=2012&amp;doi=10.1016%2Fj.humpath.2012.05.003"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR23">Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T: <strong class="EmphasisTypeBold">IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.</strong> <em class="EmphasisTypeItalic">Blood</em> 2010, <strong class="EmphasisTypeBold">116:</strong> 5486–5496. 10.1182/blood-2010-02-267955<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20805365"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2010-02-267955"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20mutations%20are%20detected%20in%206.6%25%20of%201414%20AML%20patients%20and%20are%20associated%20with%20intermediate%20risk%20karyotype%20and%20unfavorable%20prognosis%20in%20adults%20younger%20than%2060%20years%20and%20unmutated%20NPM1%20status&amp;author=S.%20Schnittger&amp;author=C.%20Haferlach&amp;author=M.%20Ulke&amp;author=T.%20Alpermann&amp;author=W.%20Kern&amp;author=T.%20Haferlach&amp;journal=Blood&amp;volume=116&amp;pages=5486-5496&amp;publication_year=2010&amp;doi=10.1182%2Fblood-2010-02-267955"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR24">Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF: <strong class="EmphasisTypeBold">The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.</strong> <em class="EmphasisTypeItalic">Leukemia</em> 2011, <strong class="EmphasisTypeBold">25:</strong> 246–253. 10.1038/leu.2010.267<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21079611"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/leu.2010.267"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20prognostic%20impact%20and%20stability%20of%20Isocitrate%20dehydrogenase%202%20mutation%20in%20adult%20patients%20with%20acute%20myeloid%20leukemia&amp;author=WC.%20Chou&amp;author=WC.%20Lei&amp;author=BS.%20Ko&amp;author=HA.%20Hou&amp;author=CY.%20Chen&amp;author=JL.%20Tang&amp;author=M.%20Yao&amp;author=W.%20Tsay&amp;author=SJ.%20Wu&amp;author=SY.%20Huang&amp;author=SC.%20Hsu&amp;author=YC.%20Chen&amp;author=YC.%20Chang&amp;author=KT.%20Kuo&amp;author=FY.%20Lee&amp;author=MC.%20Liu&amp;author=CW.%20Liu&amp;author=MH.%20Tseng&amp;author=CF.%20Huang&amp;author=HF.%20Tien&amp;journal=Leukemia&amp;volume=25&amp;pages=246-253&amp;publication_year=2011&amp;doi=10.1038%2Fleu.2010.267"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR25">Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R: <strong class="EmphasisTypeBold">Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.</strong> <em class="EmphasisTypeItalic">Am J Clin Pathol</em> 2011, <strong class="EmphasisTypeBold">135:</strong> 35–45. 10.1309/AJCPD7NR2RMNQDVF<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21173122"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1309/AJCPD7NR2RMNQDVF"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Acute%20myeloid%20leukemia%20with%20IDH1%20or%20IDH2%20mutation%3A%20frequency%20and%20clinicopathologic%20features&amp;author=KP.%20Patel&amp;author=F.%20Ravandi&amp;author=D.%20Ma&amp;author=A.%20Paladugu&amp;author=BA.%20Barkoh&amp;author=LJ.%20Medeiros&amp;author=R.%20Luthra&amp;journal=Am%20J%20Clin%20Pathol&amp;volume=135&amp;pages=35-45&amp;publication_year=2011&amp;doi=10.1309%2FAJCPD7NR2RMNQDVF"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR26">Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU: <strong class="EmphasisTypeBold">Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.</strong> <em class="EmphasisTypeItalic">J Hematol Oncol</em> 2012, <strong class="EmphasisTypeBold">5:</strong> 5. 10.1186/1756-8722-5-5<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320529"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22397365"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1186/1756-8722-5-5"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Molecular%20alterations%20of%20isocitrate%20dehydrogenase%201%20and%202%20%28IDH1%20and%20IDH2%29%20metabolic%20genes%20and%20additional%20genetic%20mutations%20in%20newly%20diagnosed%20acute%20myeloid%20leukemia%20patients&amp;author=S.%20Chotirat&amp;author=W.%20Thongnoppakhun&amp;author=O.%20Promsuwicha&amp;author=C.%20Boonthimat&amp;author=CU.%20Auewarakul&amp;journal=J%20Hematol%20Oncol&amp;volume=5&amp;pages=5&amp;publication_year=2012&amp;doi=10.1186%2F1756-8722-5-5"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR27">Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, Gale RE: <strong class="EmphasisTypeBold">The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.</strong> <em class="EmphasisTypeItalic">Blood</em> 2011, <strong class="EmphasisTypeBold">118:</strong> 409–412. 10.1182/blood-2010-12-322479<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21596855"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2010-12-322479"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20prognostic%20significance%20of%20IDH2%20mutations%20in%20AML%20depends%20on%20the%20location%20of%20the%20mutation&amp;author=CL.%20Green&amp;author=CM.%20Evans&amp;author=L.%20Zhao&amp;author=RK.%20Hills&amp;author=AK.%20Burnett&amp;author=DC.%20Linch&amp;author=RE.%20Gale&amp;journal=Blood&amp;volume=118&amp;pages=409-412&amp;publication_year=2011&amp;doi=10.1182%2Fblood-2010-12-322479"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR28">Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Lowenberg B, Valk PJ: <strong class="EmphasisTypeBold">Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.</strong> <em class="EmphasisTypeItalic">Blood</em> 2010, <strong class="EmphasisTypeBold">116:</strong> 2122–2126. 10.1182/blood-2009-11-250878<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20538800"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2009-11-250878"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Acquired%20mutations%20in%20the%20genes%20encoding%20IDH1%20and%20IDH2%20both%20are%20recurrent%20aberrations%20in%20acute%20myeloid%20leukemia%3A%20prevalence%20and%20prognostic%20value&amp;author=S.%20Abbas&amp;author=S.%20Lugthart&amp;author=FG.%20Kavelaars&amp;author=A.%20Schelen&amp;author=JE.%20Koenders&amp;author=A.%20Zeilemaker&amp;author=WJ.%20van%20Putten&amp;author=AW.%20Rijneveld&amp;author=B.%20Lowenberg&amp;author=PJ.%20Valk&amp;journal=Blood&amp;volume=116&amp;pages=2122-2126&amp;publication_year=2010&amp;doi=10.1182%2Fblood-2009-11-250878"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR29">Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, <em class="EmphasisTypeItalic">et al</em>.: <strong class="EmphasisTypeBold">Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</strong> <em class="EmphasisTypeItalic">N Engl J Med</em> 2012, <strong class="EmphasisTypeBold">366:</strong> 1079–1089. 10.1056/NEJMoa1112304<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545649"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22417203"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1056/NEJMoa1112304"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20relevance%20of%20integrated%20genetic%20profiling%20in%20acute%20myeloid%20leukemia&amp;author=JP.%20Patel&amp;author=M.%20Gonen&amp;author=ME.%20Figueroa&amp;author=H.%20Fernandez&amp;author=Z.%20Sun&amp;author=J.%20Racevskis&amp;author=P.%20Van%20Vlierberghe&amp;author=I.%20Dolgalev&amp;author=S.%20Thomas&amp;author=O.%20Aminova&amp;author=K.%20Huberman&amp;author=J.%20Cheng&amp;author=A.%20Viale&amp;author=ND.%20Socci&amp;author=A.%20Heguy&amp;author=A.%20Cherry&amp;author=G.%20Vance&amp;author=RR.%20Higgins&amp;author=RP.%20Ketterling&amp;author=RE.%20Gallagher&amp;author=M.%20Litzow&amp;author=MR.%20van%20den%20Brink&amp;author=HM.%20Lazarus&amp;author=JM.%20Rowe&amp;author=S.%20Luger&amp;author=A.%20Ferrando&amp;author=E.%20Paietta&amp;author=MS.%20Tallman&amp;author=A.%20Melnick&amp;author=O.%20Abdel-Wahab&amp;journal=N%20Engl%20J%20Med&amp;volume=366&amp;pages=1079-1089&amp;publication_year=2012&amp;doi=10.1056%2FNEJMoa1112304"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR30">Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG Jr: <strong class="EmphasisTypeBold">(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.</strong> <em class="EmphasisTypeItalic">Science</em> 2013, <strong class="EmphasisTypeBold">339:</strong> 1621–1625. 10.1126/science.1231677<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23393090"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1126/science.1231677"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=%28R%29-2-hydroxyglutarate%20is%20sufficient%20to%20promote%20leukemogenesis%20and%20its%20effects%20are%20reversible&amp;author=JA.%20Losman&amp;author=RE.%20Looper&amp;author=P.%20Koivunen&amp;author=S.%20Lee&amp;author=RK.%20Schneider&amp;author=C.%20McMahon&amp;author=GS.%20Cowley&amp;author=DE.%20Root&amp;author=BL.%20Ebert&amp;author=WG.%20Kaelin&amp;journal=Science&amp;volume=339&amp;pages=1621-1625&amp;publication_year=2013&amp;doi=10.1126%2Fscience.1231677"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR31">Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K: <strong class="EmphasisTypeBold">TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.</strong> <em class="EmphasisTypeItalic">J Clin Oncol</em> 2012, <strong class="EmphasisTypeBold">30:</strong> 1350–1357. 10.1200/JCO.2011.39.2886<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22430270"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2011.39.2886"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=TET2%20mutations%20in%20acute%20myeloid%20leukemia%20%28AML%29%3A%20results%20from%20a%20comprehensive%20genetic%20and%20clinical%20analysis%20of%20the%20AML%20study%20group&amp;author=VI.%20Gaidzik&amp;author=P.%20Paschka&amp;author=D.%20Spath&amp;author=M.%20Habdank&amp;author=CH.%20Kohne&amp;author=U.%20Germing&amp;author=M.%20von%20Lilienfeld-Toal&amp;author=G.%20Held&amp;author=HA.%20Horst&amp;author=D.%20Haase&amp;author=M.%20Bentz&amp;author=K.%20G%C3%B6tze&amp;author=H.%20D%C3%B6hner&amp;author=RF.%20Schlenk&amp;author=L.%20Bullinger&amp;author=K.%20D%C3%B6hner&amp;journal=J%20Clin%20Oncol&amp;volume=30&amp;pages=1350-1357&amp;publication_year=2012&amp;doi=10.1200%2FJCO.2011.39.2886"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR32">Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM: <strong class="EmphasisTypeBold">A “silent” polymorphism in the MDR1 gene changes substrate specificity.</strong> <em class="EmphasisTypeItalic">Science</em> 2007, <strong class="EmphasisTypeBold">315:</strong> 525–528. 10.1126/science.1135308<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17185560"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1126/science.1135308"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=A%20%E2%80%9Csilent%E2%80%9D%20polymorphism%20in%20the%20MDR1%20gene%20changes%20substrate%20specificity&amp;author=C.%20Kimchi-Sarfaty&amp;author=JM.%20Oh&amp;author=IW.%20Kim&amp;author=ZE.%20Sauna&amp;author=AM.%20Calcagno&amp;author=SV.%20Ambudkar&amp;author=MM.%20Gottesman&amp;journal=Science&amp;volume=315&amp;pages=525-528&amp;publication_year=2007&amp;doi=10.1126%2Fscience.1135308"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR33">Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, <em class="EmphasisTypeItalic">et al</em>.: <strong class="EmphasisTypeBold">Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.</strong> <em class="EmphasisTypeItalic">Science</em> 2013, <strong class="EmphasisTypeBold">340:</strong> 622–626. 10.1126/science.1234769<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23558173"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1126/science.1234769"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Targeted%20inhibition%20of%20mutant%20IDH2%20in%20leukemia%20cells%20induces%20cellular%20differentiation&amp;author=F.%20Wang&amp;author=J.%20Travins&amp;author=B.%20DeLaBarre&amp;author=V.%20Penard-Lacronique&amp;author=S.%20Schalm&amp;author=E.%20Hansen&amp;author=K.%20Straley&amp;author=A.%20Kernytsky&amp;author=W.%20Liu&amp;author=C.%20Gliser&amp;author=H.%20Yang&amp;author=S.%20Gross&amp;author=E.%20Artin&amp;author=V.%20Saada&amp;author=E.%20Mylonas&amp;author=C.%20Quivoron&amp;author=J.%20Popovici-Muller&amp;author=JO.%20Saunders&amp;author=FG.%20Salituro&amp;author=S.%20Yan&amp;author=S.%20Murray&amp;author=W.%20Wei&amp;author=Y.%20Gao&amp;author=L.%20Dang&amp;author=M.%20Dorsch&amp;author=S.%20Agresta&amp;author=DP.%20Schenkein&amp;author=SA.%20Biller&amp;author=SM.%20Su&amp;author=S.%20de%20Botton&amp;journal=Science&amp;volume=340&amp;pages=622-626&amp;publication_year=2013&amp;doi=10.1126%2Fscience.1234769"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR34">Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, Straley K, Karnik R, Meissner A, Small D, Su SM, Yen K, Zhang J, Pandolfi PP: <strong class="EmphasisTypeBold">Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.</strong> <em class="EmphasisTypeItalic">Cell Stem Cell</em> 2014, <strong class="EmphasisTypeBold">14:</strong> 329–341. 10.1016/j.stem.2013.12.016<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380188"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24440599"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.stem.2013.12.016"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Proto-oncogenic%20role%20of%20mutant%20IDH2%20in%20leukemia%20initiation%20and%20maintenance&amp;author=LM.%20Kats&amp;author=M.%20Reschke&amp;author=R.%20Taulli&amp;author=O.%20Pozdnyakova&amp;author=K.%20Burgess&amp;author=P.%20Bhargava&amp;author=K.%20Straley&amp;author=R.%20Karnik&amp;author=A.%20Meissner&amp;author=D.%20Small&amp;author=SM.%20Su&amp;author=K.%20Yen&amp;author=J.%20Zhang&amp;author=PP.%20Pandolfi&amp;journal=Cell%20Stem%20Cell&amp;volume=14&amp;pages=329-341&amp;publication_year=2014&amp;doi=10.1016%2Fj.stem.2013.12.016"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR35">Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD: <strong class="EmphasisTypeBold">Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.</strong> <em class="EmphasisTypeItalic">Blood</em> 2010, <strong class="EmphasisTypeBold">115:</strong> 453–474. 10.1182/blood-2009-07-235358<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19880497"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2009-07-235358"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Diagnosis%20and%20management%20of%20acute%20myeloid%20leukemia%20in%20adults%3A%20recommendations%20from%20an%20international%20expert%20panel%2C%20on%20behalf%20of%20the%20European%20LeukemiaNet&amp;author=H.%20Dohner&amp;author=EH.%20Estey&amp;author=S.%20Amadori&amp;author=FR.%20Appelbaum&amp;author=T.%20Buchner&amp;author=AK.%20Burnett&amp;author=H.%20Dombret&amp;author=P.%20Fenaux&amp;author=D.%20Grimwade&amp;author=RA.%20Larson&amp;author=F.%20Lo-Coco&amp;author=T.%20Naoe&amp;author=D.%20Niederwieser&amp;author=GJ.%20Ossenkoppele&amp;author=MA.%20Sanz&amp;author=J.%20Sierra&amp;author=MS.%20Tallman&amp;author=B.%20L%C3%B6wenberg&amp;author=CD.%20Bloomfield&amp;journal=Blood&amp;volume=115&amp;pages=453-474&amp;publication_year=2010&amp;doi=10.1182%2Fblood-2009-07-235358"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR36">Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD: <strong class="EmphasisTypeBold">Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.</strong> <em class="EmphasisTypeItalic">J Clin Oncol</em> 2003, <strong class="EmphasisTypeBold">21:</strong> 4642–4649. 10.1200/JCO.2003.04.036<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14673054"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2003.04.036"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Revised%20recommendations%20of%20the%20International%20Working%20Group%20for%20Diagnosis%2C%20Standardization%20of%20Response%20Criteria%2C%20Treatment%20Outcomes%2C%20and%20Reporting%20Standards%20for%20Therapeutic%20Trials%20in%20Acute%20Myeloid%20Leukemia&amp;author=BD.%20Cheson&amp;author=JM.%20Bennett&amp;author=KJ.%20Kopecky&amp;author=T.%20Buchner&amp;author=CL.%20Willman&amp;author=EH.%20Estey&amp;author=CA.%20Schiffer&amp;author=H.%20Doehner&amp;author=MS.%20Tallman&amp;author=TA.%20Lister&amp;author=F.%20Lo-Coco&amp;author=R.%20Willemze&amp;author=A.%20Biondi&amp;author=W.%20Hiddemann&amp;author=RA.%20Larson&amp;author=B.%20L%C3%B6wenberg&amp;author=MA.%20Sanz&amp;author=DR.%20Head&amp;author=R.%20Ohno&amp;author=CD.%20Bloomfield&amp;journal=J%20Clin%20Oncol&amp;volume=21&amp;pages=4642-4649&amp;publication_year=2003&amp;doi=10.1200%2FJCO.2003.04.036"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR37">Wahlin A, Billstrom R, Bjor O, Ahlgren T, Hedenus M, Hoglund M, Lindmark A, Markevarn B, Nilsson B, Sallerfors B, Brune M: <strong class="EmphasisTypeBold">Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.</strong> <em class="EmphasisTypeItalic">Eur J Haematol</em> 2009, <strong class="EmphasisTypeBold">83:</strong> 99–107. 10.1111/j.1600-0609.2009.01256.x<span class="Occurrences"><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19385987"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1111/j.1600-0609.2009.01256.x"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Results%20of%20risk-adapted%20therapy%20in%20acute%20myeloid%20leukaemia.%20A%20long-term%20population-based%20follow-up%20study&amp;author=A.%20Wahlin&amp;author=R.%20Billstrom&amp;author=O.%20Bjor&amp;author=T.%20Ahlgren&amp;author=M.%20Hedenus&amp;author=M.%20Hoglund&amp;author=A.%20Lindmark&amp;author=B.%20Markevarn&amp;author=B.%20Nilsson&amp;author=B.%20Sallerfors&amp;author=M.%20Brune&amp;journal=Eur%20J%20Haematol&amp;volume=83&amp;pages=99-107&amp;publication_year=2009&amp;doi=10.1111%2Fj.1600-0609.2009.01256.x"><span><span>Google Scholar</span></span></a></span></span></cite></li></ol></div></section><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="CopyrightMessage"><h2 class="Heading js-ToggleCollapseSection">Copyright</h2><div class="js-CollapseSection"><div xmlns="http://www.w3.org/1999/xhtml" class="ArticleCopyright">©&nbsp;Willander et al.; licensee BioMed Central Ltd.&nbsp;2014<div class="CopyrightComment">
                <p xmlns="" class="SimplePara">This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://creativecommons.org/licenses/by/4.0"><span class="RefSource">http://creativecommons.org/licenses/by/4.0</span></a></span>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://creativecommons.org/publicdomain/zero/1.0/"><span class="RefSource">http://creativecommons.org/publicdomain/zero/1.0/</span></a></span>) applies to the data made available in this article, unless otherwise stated.</p>
              </div></div></div></section></div>
                            


                        </div>
                    </div>
                    <div class="layout__sidebar-right" id="main-sidebar">
                        
                        <div class="block">
                            <aside role="complementary">
                                <div class="SideBox">
                                    
    <p class="SideBox_action">
        <a class="SideBox_pdf" id="articlePdf" target="_blank" href="/track/pdf/10.1186/2050-7771-2-18?site&#x3D;biomarkerres.biomedcentral.com" data-track-event="click" data-event-category="PDF Download"
           data-event-action="Click download article PDF"
           data-event-label="10.1186/2050-7771-2-18">Download PDF</a>
    </p>

                                    
                                    
    <h3 class="export-citations-button" data-toggle="collapse" data-target="js-exportCitations">Export citations</h3>
    <div id="js-exportCitations" class="export-citations-content panel">
        <div class="panel__section">
            <h4 class="panel__title">Citations & References</h4>
            <ul class="ListDownload" id="articleReferences">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks citations and references"
                       data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=refman&flavour=full">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote citations and references" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=endnote&flavour=full">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef citations and references" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=bibtex&flavour=full">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">Article citation</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks article citations" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=refman&flavour=citation">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote article citations" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=endnote&flavour=citation">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef article citations" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=bibtex&flavour=citation">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">References</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks references" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=refman&flavour=references">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote references" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=endnote&flavour=references">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef references" data-event-label="10.1186/2050-7771-2-18"
                       href="http://citation-needed.springer.com/v2/references/10.1186/2050-7771-2-18?format=bibtex&flavour=references">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
    </div>

                                </div>
                                <div class="SideBox">
                                    <nav xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="ArticleNavigation" class="table-of-contents" aria-label="table of contents"><div class="table-of-contents__content" data-sticky="toc"><h3 class="table-of-contents__title is-open" data-toggle="collapse" data-target="tocMenu" data-event-category="Table of Contents" data-track-event="click" data-event-action="Toggle ToC" data-event-label="Toggle" data-toggle-disable-clickoff="true" aria-expanded="true">Table of Contents</h3><ul class="table-of-contents__menu is-open" role="menu" id="tocMenu" aria-expanded="true"><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Abs1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Abstract">Abstract</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Background">Background</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec2" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Results">Results</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec6" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Discussion">Discussion</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec7" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Conclusions">Conclusions</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec8" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Methods">Methods</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec12" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Authors’ information">Authors’ information</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Declarations" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Declarations">
                        Declarations
                      </a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Bib1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="References">References</a></li><li role="menuitem" class="table-of-contents__item is-hidden"><a class="table-of-contents__link" href="#comments" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Comments">Comments</a></li></ul></div></nav>
                                </div>
                                <div class="SideBox">
                                    <h3 class="SideBox_title">Metrics</h3>
                                    <ul class="SideBox_list list-stacked list-stacked--small list-stacked--2">
                                        <div id="article-access-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/access-count/10.1186/2050-7771-2-18 #accessCount-container"></div>
                                        <div id="citation-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/citation-count/10.1186/2050-7771-2-18 #count-container"></div>
                                        <div id="altmetric-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/altmetric/10.1186/2050-7771-2-18 #altmetric-container"></div>
                                    </ul>
                                </div>
                                
    <div id="sociaMediaShare" class="SideBox">
        <h3 class="SideBox_title">Share this article</h3>
        <ul id="shareButtons" class="share">
            <li class="share__item">
                <button id="shareOnTwitter" class="js-btnShareOnTwitter share__button share__button--twitter" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Twitter" data-event-label="10.1186/2050-7771-2-18">
                    <span class="sr-only">Share on Twitter</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnFacebook" class="js-btnShareOnFacebook share__button share__button--facebook" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Facebook" data-event-label="10.1186/2050-7771-2-18">
                    <span class="sr-only">Share on Facebook</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnLinkedIn" class="js-btnShareOnLinkedIn share__button share__button--linkedin" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share LinkedIn" data-event-label="10.1186/2050-7771-2-18">
                    <span class="sr-only">Share on LinkedIn</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnWeibo" class="js-btnShareOnWeibo share__button share__button--weibo" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Weibo" data-event-label="10.1186/2050-7771-2-18">
                    <span class="sr-only">Share on Weibo</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnGooglePlus" class="js-btnShareOnGplus share__button share__button--gplus" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Google+" data-event-label="10.1186/2050-7771-2-18">
                    <span class="sr-only">Share on Google Plus</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnReddit" class="js-btnShareOnReddit share__button share__button--reddit" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Reddit" data-event-label="10.1186/2050-7771-2-18">
                    <span class="sr-only">Share on Reddit</span>
                </button>
            </li>
        </ul>
    </div>

                                
    
    <div class="SideBox">
        <h3 class="SideBox_title">See updates</h3>
        <a data-crossmark="10.1186/2050-7771-2-18" rel="modal:open" href="#crossmark-dialog" data-track-event="click" data-event-category="Article Page" data-event-action="Click CrossMark" data-event-label="10.1186/2050-7771-2-18">
            <img class="CrossMark" id="crossmark-icon" src="/static/images/crossmark-c0483e404d.png" alt="Click to get updates and verify authenticity" />
        </a>
        <div id="crossmark-dialog" class="u-isHidden">
            <iframe id="crossmark-iframe" frameborder="0" width="550" height="550"></iframe>
        </div>
        <div class="Modal" data-modal="wrap">
            <div class="Modal_inner">
                <a rel="modal:close" id="close-10.1186/2050-7771-2-18" class="Icon Icon--cross-default"></a>
                <div class="Modal_content" data-modal="content"></div>
            </div>
        </div>
    </div>
    

                                
    

                                
    

                                <div class="SideBox">
                                    <h3 class="SideBox_title">Other Actions</h3>
                                    <ul class="list-stacked list-stacked--2 list-stacked--small">
                                        <li class="list-stacked__item">
                                            
    <a data-track-event="click" data-event-category="Article Page" data-event-action="Order article reprints" data-event-label="10.1186/2050-7771-2-18" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186%2F2050-7771-2-18&volume=2&issue=1&title=Mutations+in+the+isocitrate+dehydrogenase+2+gene+and+IDH1+SNP+105C%E2%80%89%3E%E2%80%89T+have+a+prognostic+value+in+acute+myeloid+leukemia&author_name=Kerstin+Willander&start_page=1&end_page=9">Order reprint</a>

                                        </li>
                                    </ul>
                                </div>
                                
        
    
                            </aside>
                            
    <div id="FulltextAd" class="adsbox Ad Ad--skyscraper">
        <div class="Ad_content">
            <p class="Ad_label">Advertisement</p>
            <span id="pbgrd-43415139"></span>
        </div>
    </div>

                        </div>
                    </div>
                </div>
            </div>
        </main>
        
            <div class="journal-footer">
                <div class="journal-footer__inner">
                    <div class="journal-footer__summary">
                        <h4 class="journal-footer__title">
                            
                            <span class="journal-footer__title-text">Biomarker Research</span>
                        </h4>
                        <p class="journal-footer__issn">ISSN: 2050-7771</p>
                    </div>
                    
                        <div class="journal-footer__contact">
                            <h4 class="journal-footer__contact-title">Contact us</h4>
                            <ul class="journal-footer__contact-list">
                                
                                    <li class="journal-footer__contact-item">Editorial email: <a href="mailto:may.seron@biomedcentral.com">may.seron@biomedcentral.com</a></li>
                                
                                
                                    <li class="journal-footer__contact-item">Support email: <a href="mailto:info@biomedcentral.com">info@biomedcentral.com</a></li>
                                
                            </ul>
                        </div>
                    
                </div>
            </div>
        
         
    <footer>
        <div class="footer">
            <div class="footer__header">
                <img srcset="/static/images/biomed-central-logo-white-3c6c941205.svg" src="/static/images/biomed-central-logo-white-faac4202d5.png" class="logo__img footer__logo" alt="Biomed Central" />
                
                    <h2 class="footer__menu-title">Publisher Main Menu</h2>
                    <ul class="footer__primary-menu">
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/journals">Explore journals</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/getpublished">Get published</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/about">About BioMed Central</a>
                            </li>
                        
                    </ul>
                
            </div>
            <div id="Test-FooterExists" class="footer__content">
                <div class="footer__legal">
                    
                    <p class="footer__terms">By continuing to use this website, you agree to our <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/terms-and-conditions">Terms and Conditions</a>, <a class="footer__link footer__link--inline"
                                                                                                                                                                                                                               href="//www.biomedcentral.com/terms-and-conditions/privacy-statement">Privacy
                        statement</a> and <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/cookies">Cookies</a> policy.</p>
                </div>
                
    <nav id="publisherFooter" class="footer__nav">
        <h3 class="footer__menu-title">Publisher secondary menu</h3>
        <div class="footer__nav-inner">
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://blogs.biomedcentral.com/">Read more on our blogs</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/login">Receive BMC newsletters</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/account">Manage article alerts</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/language-editing/">Language editing for authors</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/scientific-editing/">Scientific editing for authors</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/policies">Policies</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/accessibility">Accessibility</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/press-centre">Press center</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/contact-us">Contact us</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="https://biomedcentral.typeform.com/to/VLXboo">Leave feedback</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/jobs">Careers</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu footer__menu--follow">
                <div class="footer__follow">
                    <h3 class="footer__follow-title">Follow BioMed Central</h3>
                    <ul class="follow follow--inline">
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--twitter" href="https://twitter.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Twitter">
                                <span class="follow__label">Twitter</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--facebook" href="https://www.facebook.com/BioMedCentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Facebook">
                                <span class="follow__label">Facebook</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--gplus" href="https://plus.google.com/106226337984152901734/" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Google Plus">
                                <span class="follow__label">Google Plus</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--weibo" href="http://www.weibo.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Weibo">
                                <span class="follow__label">Weibo</span>
                            </a>
                        </li>
                    
                    </ul>
                </div>
            </div>
        </div>
    </nav>


            </div>
        </div>
        <div class="branding-bar">
            <div class="logo branding-bar__logo">
                <img srcset="/static/images/logo-springernature-4230d19d5c.svg" src="/static/images/logo-springernature-828f4f84c8.png" class="logo__img branding-bar-logo__img" alt="Springer Nature Logo" />
            </div>
            <p class="branding-bar__copyright">&#169; 2017 BioMed Central Ltd unless otherwise stated. Part of <a class="branding-bar__link" href="http://www.springernature.com">Springer Nature</a>.</p>
        </div>
    </footer>
    <noscript class="js-cookie-banner-noscript">
        <div class="cookie-banner js-cookie-banner">
            <div class="cookie-banner__inner">
                <p class="cookie-banner__message">
                    We use cookies to improve your experience with our site.
                    <a href="https://www.biomedcentral.com/cookies"
                       class="cookie-banner__link"
                       data-track-event="click"
                       data-event-category="EU Cookie Law Banner"
                       data-event-action="Find out more">More information <span class="sr-only">about our cookie policy</span>
                    </a>
                </p>
                <button hidden class="cookie-banner__dismiss js-cookie-banner-dismiss"
                        data-track-event="click"
                        data-event-category="EU Cookie Law Banner"
                        data-event-action="Close"><span class="cookie-banner__dismiss-text">Close</span>
                </button>
            </div>
        </div>
</noscript>


    </div>
    
    <img class='tracker' style='display:none' src='/track/article/10.1186/2050-7771-2-18' alt=""/>

    <div id="JFulltext"></div>

    
    <script type="text/javascript" src="//cdn.pbgrd.com/bmc.js" async="async"></script>

    

    
<script>
(function() {
    var linkEl = document.querySelector('.js-ctm');
    if (linkEl && window.matchMedia && window.matchMedia(linkEl.media)) {
        var vendorScript = document.createElement('script');
        vendorScript.src = '/static/js/oscar-vendor-67103b4f35.js';
        vendorScript.async = false;
        document.body.appendChild(vendorScript);
        var appScript = document.createElement('script');
        appScript.src = '/static/js/oscar-app-4e91ea0ef9.js';
        appScript.async = false;
        document.body.appendChild(appScript);
    }
})();
</script>



<script type="text/javascript">
    if (config) {
        (function (d) {
            Array.prototype.forEach.call(d.getElementsByClassName('RealMediaAd'), function (adElement) {
                var iframe = d.createElement('iframe');
                iframe.frameBorder = '0';
                iframe.scrolling = 'no';
                var position = adElement.getAttribute("data-position"),
                        iframeInDoc = adElement.getElementsByClassName('Ad_content')[0].appendChild(iframe),
                        doc = iframeInDoc.contentWindow.document;

                doc.open().write('<body onload="window.location.href = '
                        + '\'/placeholder/v1/advertising/realMedia?siteWithPath=' + encodeURIComponent(config.siteWithPath)
                        + '&placement=' + position + '\';">');
                doc.close();
            });
        })(document);
    }
</script>



    
        <script type="text/javascript">
            document.addEventListener('readystatechange', function () {
                if (document.readyState === 'complete') {
                    setTimeout(function () {
                        var script = document.createElement("script");
                        script.type = "text/javascript";
                        script.src = "https://recommendations.springernature.com/latest/entry-point.js";
                        document.getElementsByTagName("head")[0].appendChild(script);
                    }, 0);
                }
            });
        </script>
    


    <script type="text/javascript">
        var _kiq = _kiq || [];
        (function () {
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/9CC.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/aC6.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
        })();
    </script>


<noscript>
	<img hidden src="https://verify.nature.com/verify/nature.png" border="0" width="0" height="0" style="display: none">
</noscript>
</body>
</html>

